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Purpose: This study examined the influence of genotype polymorphisms (specifically 
ACTN3 R577X, IGF-II C13790C, IGF-II G17200A, IGF2AS A1364C, IGF2AS 
G11711T) on markers of skeletal muscle recovery following an acute bout of heavy 
endurance exercise, and assessed their role in determining individual responses to 
carbohydrate-protein supplementation. Methods: Twelve trained male cyclists completed 
repeated cycling trials, each consisting of an initial session of glycogen-depleting 
exercise, followed four hours later by a >1 hr time-trial on a computerized cycle 
ergometer (VeloTron, Racermate, Inc). Subjects were randomly administered a high-
carbohydrate low-protein (HCLP), or carbohydrate-only (CHO) beverage, which was 
consumed immediately and 2-hours post glycogen depleting exercise, and immediately 
following subsequent exercise. Beverages were isocaloric and isovolumetric.
 
Blood 
samples were obtained before the glycogen-depleting exercise of the first trial for 
genotyping analysis. Serum creatine kinase (CK), peak muscle function (MVC), mental 
and physical energy and fatigue ratings, and muscle soreness ratings were obtained as 
markers of muscle recovery at specific time points. Subjects completed these methods for 
both treatments in a double-blind protocol. Results: Changes in MVC were significantly 
different (P < 0.05) from baseline to 4-hours post glycogen depleting exercise among 
genotypes for the ACTN3 R577X, IGF-II C13790C, and IGF2AS A1364C single 
nucleotide polymorphisms (SNPs) during the CHO control trial. Changes in 
mental/physical energy/fatigue and muscle soreness ratings were significantly different 
(P < 0.05) from baseline to 24-hours post glycogen depleting exercise among genotypes 





variables tended to improve with the HCLP treatment when subjects identified for the 
above genotype variations were analyzed, although the improvements were not 
statistically significant. Changes in serum CK were not significantly different (P > 0.05) 
from baseline to 4-hours post glycogen depleting exercise among genotypes analyzed. 
Conclusions: Genotype variations led to significant differences in MVC, physical/mental 
energy/fatigue and muscle soreness ratings, which tended to improve with the HCLP 
treatment. There were no genotype effects for serum CK. 
































 This study shall attempt to analyze the roles of genotypes on the extent of muscle 
damage, and the subsequent rate of muscle recovery, following intense aerobic exercise. 
The findings should enhance understanding of the variations in response to post-exercise 




Prolonged high-intensity endurance exercise is associated with depleted glycogen 
stores and impairments in markers of muscle recovery. Traditionally, sports beverages 
containing water, carbohydrate, and electrolytes have been utilized by endurance athletes 
to enhance glycogen replenishment, facilitate muscle recovery, and improve aerobic 
performance (Hargreaves et al., 1984; Coyle and Coggan, 1984; Coggan and Coyle 1991; 
Coyle, 1992; 1992; Halson, 2004). Recently, the inclusion of protein into carbohydrate-
based sport beverages to confer additional performance benefits has garnered 
considerable attention in the field of exercise science. The inclusion of protein content is 
proposed to enhance the rate of muscle recovery, as well as improve subsequent 
endurance performance (Saunders et al., 2004; Betts et al., 2007; Berardi et al., 2008; 
Rowland et al., 2008; and Skillen et al., 2008). 
Current studies examining the efficacy of carbohydrate-protein supplementations 
have demonstrated mixed results. Some studies have documented improved performance 
in subsequent exercise bouts (Saunders et al., 2004; Betts et al., 2007; Berardi et al., 





muscle damage and soreness (Saunders et al., 2004; Millard-Stafford et al., 2005; 
Romano-Ely et al., 2006; Rowland et al., 2008; and Skillen et al., 2008) with 
carbohydrate-protein ingestion. However, other studies have reported no differences in 
subsequent exercise performances between carbohydrate and carbohydrate-protein 
beverages (Millard-Stafford et al., 2005; Romano-Ely et al., 2006; Betts et al., 2007). In 
addition to the variations between studies, there appears to be considerable variations 
among individual subjects with respect to the potential efficacy of carbohydrate-protein 
ingestion. For example, Combest et al. (2005) reported that 10 of 14 cyclists performing 
exhaustive exercise observed sizable attenuations in post-exercise serum CK levels (ΔCK 
= 975 ± 590 U/L) with carbohydrate-protein ingestion, while the remaining four subjects 
were non-responders (ΔCK = -10.0 ± 31.6 U/L) to carbohydrate-protein intake. 
Furthermore, the carbohydrate-protein „responders‟ experienced improvements in 
subsequent exercise performance that were significantly greater than those who were 
„non-responders‟. 
The variations in findings within current literature suggest that some individuals 
are better responders to carbohydrate-protein supplementation than others, although the 
mechanism for the variations remains unclear. One possible explanation may lie in the 
role of specific genetic polymorphisms. Certain genotypes may predispose individuals to 
greater muscle damage following exercise. Hence, such individuals would potentially 




Current studies examining genotype associations with muscle damage have 





acute exercise: MLCK C37885A (Clarkson et al., 2005), IGF-II C13790G, IGF-II 
G17200A, IGF2AS A1364C, IGF2AS G11711T (Devaney et al., 2007), and ACE ID 
(Yamin et al., 2007). However, these studies have primarily incorporated eccentric 
resistance exercise protocols. The association between genotypes and aerobic exercise-
induced muscle damage is therefore not well understood.  
Hence, the present study seeks to determine if genetic polymorphisms influence 
muscle damage/recovery variables following heavy endurance exercise. This would 
address and account for the wide variations in responses to performance recovery 




 This study seeks to evaluate the influence of genetic polymorphisms (specifically 
IGF-II C13790G, IGF-II G17200A, IGF2AS A1364C, IGF2AS G11711T, and ACTN3 
R577X) on the rate of muscle recovery, as measured by serum creatine kinase (CK) 
levels, peak muscle function (MVC), perceived muscle soreness, and ratings of 
energy/fatigue following heavy endurance exercise. The findings may help to determine 




1) The variations between genotypes among subjects will lead to significant differences 
in the following muscle damage variables after acute heavy endurance exercise: 
serum CK levels, peak muscle function (MVC), perceived physical and mental 





2) Subjects with genotypes that are associated with greater increases in the above muscle 
damage variables will derive significant reductions in these variables, and significant 
improvements in time to completion during a subsequent endurance performance 
exercise with the ingestion of high carbohydrate – low protein beverages. 
 
Assumptions 
1) Subjects participated in a maximal cycle test before the start of the study to determine 
their VO2peak and maximal power. The oxygen uptake measurement served as an 
exclusion criterion, while the power score was used to determine workload performed 
during the glycogen depleting exercise, and the steady state portion of the subsequent 
exercise. Therefore, it was assumed that all subjects provided a maximal effort during 
this test.  
2) Subjects completed a maximum voluntary isometric contraction of the quadriceps to 
assess peak muscle function on five separate occasions for each trial. It was assumed 
that subjects gave a maximal effort during each of these occasions.  
3) It was assumed that subjects adhered to instructions to consume no other calories 
other than their standardized breakfast 12-hours prior to each training session. It was 
also assumed that subjects did not consume any calories besides the treatment 
provided during the 4-hour recovery period between the glycogen depleting exercise 
and the subsequent time-trial. It was finally assumed that subjects did not consume 






4) Subjects were instructed to treat each subsequent time-trial as a competitive race, and 
provide a maximal effort. It was therefore assumed that subjects provided a maximal 
effort during their subsequent performance rides. 
 
Definition of Terms 
 
1) Genotype: genetic constitution of an organism, determined by the allele composition. 
2) Allele: Variations in DNA sequence in a chromosome (DNA and protein structure 
found in cells). 
 - Heterozygous: possessing 2 different variants of an allele. 
 - Homozygous: possessing identical alleles. 
3) Polymorphism: Common variations of DNA resulting from mutations. 
4) Single Nucleotide Polymorphism (SNP): Variation in DNA sequence between 
individuals involving a single nucleotide– A, G, C, T (nucleotides are molecules that 















Review of Literature 
 
Carbohydrate-based sports beverages have been demonstrated to improve athletic 
performance during heavy endurance exercise. The addition of protein into carbohydrate-
based sport beverages to confer additional performance benefits in aerobic exercise has 
been recently investigated within the last decade. Current literature is inconclusive on the 
effectiveness of carbohydrate-protein supplementation as performance enhancement 
beverages for acute endurance exercise (Table 2.1). Some studies have demonstrated 
enhanced cycling time trial performance and time to fatigue with carbohydrate-protein 
ingestion. Conversely, other studies reported a lack of substantial improvements in time 
to exhaustion and time to completion when protein calories were added into carbohydrate 
beverages.  
When utilized as a performance recovery beverage, current literature is more 
positive on the effectiveness of carbohydrate-protein supplementation in subsequent 
endurance performance (Table 2.2), as evidenced by improvements in subsequent time 
trial performances and times to exhaustion. Studies examining physiological recovery 
variables have reported attenuated plasma CK levels, and reduced levels of perceived 
muscle soreness following heavy endurance exercise with carbohydrate-protein 
supplementation. Despite these documented benefits, there are variations between studies 
in the magnitude and extensiveness of the benefits among subjects. One possible 
explanation for the variability in recovery benefits with carbohydrate-protein 
supplementation, as well as the variations in findings on acute endurance exercise, may 





Genotyping studies have revealed that genetic variations may account for 
differences in sport performance (Table 2.3), muscle function (Table 2.4), and skeletal 
muscle damage accrued following exercise (Table 2.5). In sports performance, the 
ACTN3 R allele and RR genotype are associated with enhanced sprint performance, 
whereas the ACTN3 X allele and XX genotype are associated with augmented endurance 
performance. For muscle function, the ACE D allele and ACE DD genotype are 
associated with increased type II fiber distribution, and improved muscular strength, 
whereas the ACE I allele and ACE II genotype are associated with increased type I fiber 
distribution. In terms of skeletal muscle damage, MLCK C37885A, IGF II G/C, IGF2AS 
A1364C, IGF2AS G11711T, and ACE II allele have been identified with increased CK 
levels and/or strength loss following resistance exercise protocols. 
The present study aims to examine the influence of genotypes on the rate of 
muscle recovery following heavy endurance exercise, which may help determine 














Table 2.1: Carbohydrate and Protein and Acute Endurance Performance. 
Articles Problem/Question 
studied 
Participants Procedures Findings 








intensity (Ivy et 
al., 2003) 
To compare the 










9 trained male 
cyclists (27.3 + 
1.3 yr, 69.6 + 
2.5 kg, 52.6 + 
10.3 ml/kg/min) 
Subjects performed three 
trials of cycle ergometry 
at 45 – 75% of VO2max 
for 3 hr, and then at 85% 
VO2max to exhaustion. 
During each separate 
trial, subjects were 
administered 200 ml of 
the sweetened placebo, a 
7.75% liquid 
carbohydrate supplement, 
or a 7.75%/1.94% protein 
supplement immediately 
prior to the start of 
exercise, and every 20 
minutes during exercise, 
until 85% VO2max was 
achieved. Subsequent 
trials were performed 7 – 
14 days apart with the 
alternate treatment 
beverages. 
The time to exhaustion 
was significantly longer 
with consumption of the 
carbohydrate-only 
supplement, when 
compared to the placebo. 
The time to exhaustion 
was significantly longer 
with consumption of the 
carbohydrate-protein 
supplement, when 





ratio, blood glucose, 
plasma insulin, plasma 
free fatty acid, and blood 
lactate) did not differ 
significantly between the 
carbohydrate-only and 
carbohydrate protein 
treatments. These findings 
suggest that the addition 




above that of a 
carbohydrate-only 
supplement, although the 
mechanism behind this 
benefit is not completely 
understood. 







and Todd, 2004) 
To compare the 










15 trained male 
cyclists (20.9 + 
3.3 yr, 73.3 + 
6.4 kg, 52.6 + 
10.3 ml/kg/min) 
Subjects performed two 
trials of cycle ergometry 
to exhaustion (at 75% 
and 85% VO2peak 
respectively, 12 – 15 hr 
apart). Subjects were 
administered 1.8 ml/kg 
bodyweight of randomly 
assigned carbohydrate or 
carbohydrate-protein 
beverage every 15 
minute during exercise, 
and 10 ml/kg bodyweight 
of the same treatment 
post-exercise. The 
protocol was repeated 7 – 
14 days later with the 
other treatment beverage.   
The time to exhaustion 
was significantly longer in 
the initial performance 
ride with consumption of 
the carbohydrate-protein 
beverage, when compared 
to the carbohydrate-only 
beverage (P < 0.05). This 
finding demonstrates a 
significant improvement 
in acute cycling times to 
exhaustion with the 
addition of protein 













when added to a 
sports drink 
(Van Essen and 
Gibala, 2006) 
To compare the 
effects of adding 
2% protein to a 6% 
carbohydrate 
beverage on 80 km 
cycling time trial 
performances 
against a 6% 
carbohydrate drink 
and a nonenergetic 
sweetened placebo. 
10 trained male 
cyclists (24 + 2 
yr, 76 + 2 kg, 63 
+ 2 ml/kg/min) 
Subjects performed three 
separate 80 km time trials 
on the cycle ergometer. 
During each separate 
trial, subjects were 
administered 250 ml of 
the carbohydrate-protein, 
carbohydrate, or placebo 
beverage every 15 
minutes during exercise. 
Subsequent trials were 
performed 7 days apart 
with the alternate 
treatment beverages.  
The times to completion 
were significantly faster 
with consumption of the 
carbohydrate-protein and 
carbohydrate beverages, 
than with consumption of 
the placebo (P < 0.002). 
There were no significant 
differences in time to 
completion between the 
carbohydrate-protein and 
carbohydrate beverages (P 
= 0.92). These findings 
suggest that while the 
carbohydrate-protein 
beverage improved 80 km 
cycle time trial 
performances, additional 
protein content does not 
appear to confer further 
benefits in improving the 
time to completion. 









To compare the 
effects of a 
carbohydrate-
protein-antioxidant 







14 trained male 
cyclists (24.0 + 
4.1 yr, 59.8 + 
11.9 ml/kg/min) 
Subjects performed two 
trials of cycle ergometry 
to exhaustion (at 70% 
and 80% VO2peak 
respectively, 24 hr apart). 
Subjects were 
administered 2.0 ml/kg 




beverage every 15 
minutes during exercise, 
and 10 ml/kg bodyweight 
of the same treatment 
post-exercise. The 
protocol was repeated 1 – 
2 weeks later with the 
alternate treatment 
beverage.   
The times to fatigue were 
not significantly different 
between the two treatment 
beverages in the initial 
70% VO2peak trial (P = 
0.77), and in the 
subsequent 80% VO2peak 
trial (P = 0.91). Post-
exercise CK levels (P < 
0.05) and 24 hr CK levels 
(P < 0.05) were 




Post-exercise LDH levels 
(P < 0.05) and 24 hr LDH 
levels (P < 0.05) were 




Peak muscle soreness 
levels 24 hr post-exercise 




antioxidant ingestion (P < 
0.05). These findings 





damage and subjective 
muscle soreness, but the 
additional protein content 
did not improve time to 


















To compare the 
effects of an oral-
carbohydrate-
protein gel against 
a carbohydrate 









cyclists: 8 males 
(23.8 + 7.4 yr, 
74.8 + 10.1 kg, 
61.5 + 4.2 
ml/kg/min), 5 
females (24.8 + 
6.4 yr, 61.1 + 
7.0 kg, 51.3 + 
4.9 ml/kg/min) 
Subjects performed two 
bouts of cycle ergometry 
to exhaustion at 75% 
VO2peak. Subjects were 
randomly administered 
carbohydrate-protein or 
carbohydrate only gels 
every 15 minutes during 
exercise, and the same 
treatment with water 
immediately post-
exercise. The protocol 
was repeated 7 – 14 days 
later with the alternate 
treatment beverage.   
The time to exhaustion 
was significantly longer 
with ingestion of the 
carbohydrate-protein gel, 
than the carbohydrate-only 
gel (P < 0.05). There were 
no gender differences in 
time to exhaustion (P = 
0.98). The increase in CK 
levels post-exercise was 
significantly lower with 
ingestion of the 
carbohydrate-protein gel 
(P < 0.05). These findings 
suggest that ingestion of a 
carbohydrate-protein gel 
during and after exercise 
improves cycling 
endurance performance, 










(Valentine et al., 
2008) 




ingestion on time 
to exhaustion and 







(CHO) and total 
calories 
11 trained male 
cyclists (20.8 + 
2.4 yr, 75.2 + 
11.6 kg, 53.4+ 
7.2 ml/kg/min) 
Subjects performed four 
separate cycle ergometry 
rides to exhaustion at 
75% VO2peak, at a 
cadence of 50 rpm. 
Subjects were randomly 
administered 250 ml of a 
placebo, a carbohydrate 
only (6%) beverage, a 
higher dosage (9.69%) of 
carbohydrate beverage, 
or a carbohydrate 
(7.75%) and protein 
(1.94%) beverage every 
15 min until fatigue. 
Subsequent trials were 
performed 5-7 days apart 
with the alternate 
treatment beverages. 
The cycling times to 
exhaustion were 
significantly longer with 
the carbohydrate-protein 
and the higher dosage of 
carbohydrate beverages, 
than the placebo (P < 
0.05). There were no 
significant differences in 
times to exhaustion 
between the lower dosage 
carbohydrate beverage and 
the placebo, or between 
the carbohydrate-protein 
beverage, the higher 
dosage of carbohydrate 
beverage, and the lower 
dosage of carbohydrate 
beverage. Post-exercise 
plasma creatine kinase and 
serum myoglobin were 
lower during the 
carbohydrate-protein trial 
than all the other 
treatments. The number of 
24hr post-exercise leg 
extensions performed at 
70% of 1 RM was 
significantly greater in the 
carbohydrate protein trial 
than all other treatments. 
These findings suggest 
caloric differences may 




improvements in muscle 
recovery variables are 
independent of caloric 





















relative to placebo 
and carbohydrate 
13 trained male 
cyclists (31.2 + 
2.4 yr, 73.4 + 
9.0 kg, 56.0 + 
6.9 ml/kg/min) 
Subjects performed three 
separate experimental 
trials of constant-load 
cycle ergometry for 120 
min, followed 
immediately by a time-
trial in which they 
completed a set amount 
of work as quickly as 
possible (7 kJ/kg). 
Subjects were randomly 
administered 250 ml of a 
placebo, a carbohydrate 
only (6%) beverage, or a 
carbohydrate (7.5%) and 
protein (1.6%) beverage 
every 15 min during the 
constant-load ride. 
Subsequent trials were 
performed 5-7 days apart 
with the alternate 
treatment beverages. 
The time trial performance 
was significantly faster (P 
< 0.05), and the power 
output during the time trial 
was significantly higher (P 
< 0.05) with ingestion of 
the carbohydrate-only 
beverage, compared to the 
placebo. The time trial 
performance and power 
output during the time trial 
were not significantly 
different with ingestion of 
the carbohydrate-protein 
beverage, than either the 
carbohydrate-only or 
placebo beverage. The 
RPE, heart rate, and 
percent hydration during 
the constant-load ride 
were not different between 
all three treatments. These 
findings suggest that the 
carbohydrate-protein 
beverage provide no 










(Saunders et al., 
2009) 
To compare the 
effects of a 
carbohydrate-
casein hydrolysate 
beverage against a 
carbohydrate only 
beverage on 
cycling time trial 
performance, and 
markers of muscle 
disruption and 
recovery. 
13 trained male 
cyclists (25.3 + 
2.4 yr, 73.0 + 
2.6 kg, 60.8 + 
1.6 ml/kg/min) 
Subjects performed two 
simulated 60 km cycle 
time trials with a 5% 
grade in the last 5 km. 
Subjects were 
administered 200 ml 
randomly assigned 
carbohydrate-only 
beverage (6%) or 
carbohydrate-casein 
hydrolysate beverage 
(6% + 1.8%) every 5 km 
during exercise, and 500 
ml of the same treatment 
immediately post-
exercise. The protocol 
was repeated 7 – 10 days 
later with the alternate 
treatment beverage.   
The riding times in the 
final 20 km of the time 
trials and the last 5 km 
with 5% grade were 
significantly faster with 
ingestion of the 
carbohydrate-casein 
hydrolysate beverage, 
when compared to the 
carbohydrate-only 
beverage (P < 0.05). Post-
exercise plasma CK levels 
and muscle soreness 
ratings were significantly 
elevated with ingestion of 
the carbohydrate-only 
beverage (P < 0.05), but 
not with carbohydrate-
casein hydrolysate 
beverage. These findings 
suggest that the addition 
of casein hydrolysate to a 
carbohydrate beverage 




elevations in plasma CK 
















et al., 2009) 








and markers of 
muscle disruption. 
10 trained male 
cyclists and 
runners: 25.7 + 
3.4 yr, 72.6 + 
3.2 kg, 51.7 + 
2.6 ml/kg/min 
(bike VO2peak), 




Subjects performed three 
simulated duathlons, 
consisting of an 8 km 
treadmill run at 80% 
VO2max, simulated 50 
km cycle ergometer ride 
at 70% VO2max, and 
subsequent treadmill run 
at 80% VO2max until 
fatigue. Subjects were 




carbohydrate + 1% 
protein hydrolysate 
beverage, or 
carbohydrate + 2% 
protein hydrolysate 
during the cycle exercise. 
Subsequent trials were 
performed 6 – 10 days 
apart with the alternate 
treatment beverages. 
The time to exhaustion 
was significantly longer in 
the subsequent treadmill 
run with ingestion of the 
carbohydrate + 1% protein 
hydrolysate beverage, than 
with the carbohydrate-
only beverage (P < 0.05). 
Post-exercise plasma CK 
levels were significantly 
lower with ingestion of the 
carbohydrate + 2% protein 
hydrolysate beverage, than 
the other two treatments. 
Post-exercise muscle 
soreness ratings were 
significantly lower with 
ingestion of the 
carbohydrate + 2% protein 
hydrolysate, than with the 
carbohydrate-only 
beverage. The decline in 
pre- to post-exercise peak 
isometric force (MVC) 
was significantly greater 
with the carbohydrate-
only ingestion, than the 
other two treatments. 
These findings suggest the 
addition of small amounts 
of protein hydrolysate to a 
carbohydrate beverage 
improves time to fatigue 
in endurance exercise, 
whereas a larger amount 
of protein hydrolysate 
attenuates muscle damage 
associated with heavy 
endurance exercise.   
Added Protein 
Maintains 





Lagunas et al., 
2010) 






and a low-calorie 
carbohydrate-
protein beverage 
against a 6% 
carbohydrate 
sports beverage. 
12 (5 females 
and 7 males) 
trained cyclists 
(28.3 + 1.4 yr, 
65.7 + 2.3 kg, 
57.3 + 2.7 
ml/kg/min), 
Subjects performed four 
separate rides between 55 
– 75% VO2max for 2.5 
hours, and then at 80% 
VO2max until fatigue. 
Subjects were randomly 
administered 255.4 + 9.1 
ml of a placebo, a 
carbohydrate only (6%) 
beverage, a higher 
dosage of carbohydrate 
(4.5%) and protein 
(1.15%) beverage, and a 
lower dosage of 
carbohydrate (3%) and 
protein (0.75%) beverage 
every 20min. Subsequent 
trials were performed 7 
days apart with alternate 
treatment beverages. 
The times to exhaustion 
were significantly longer 
in the carbohydrate-only, 
high and low dosages of 
carbohydrate-protein 
beverages, than the 
placebo (P < 0.05), with 
no significant differences 
between the 3 treatments. 
These 3 treatments also 
reported elevated blood 
glucose, plasma insulin, 
carbohydrate oxidation, 
and lower levels of free 
fatty acids, rates of fat 
oxidation, RPE compared 
to the placebo. This study 
suggests adding protein to 
sports recovery drinks is 
effective in enhancing 
aerobic capacity, while 






Table 2.2: Carbohydrate and Protein and Post-Exercise Recovery. 
Articles Problem/Question 
studied 
Participants Procedures Findings 







and Todd, 2004) 
To compare the 










15 trained male 
cyclists (20.9 + 
3.3 yr, 73.3 + 
6.4 kg, 52.6 + 
10.3 ml/kg/min) 
Subjects performed two 
trials of cycle ergometry 
to exhaustion (at 75% 
and 85% VO2peak 
respectively, 12 – 15 hr 
apart). Subjects were 
administered 1.8 ml/kg 
bodyweight of randomly 
assigned carbohydrate or 
carbohydrate-protein 
beverage every 15 
minute during exercise, 
and 10 ml/kg bodyweight 
of the same treatment 
post-exercise. The 
protocol was repeated 7 – 
14 days later with the 
other treatment beverage.   
The time to exhaustion 
was significantly longer in 
the subsequent 
performance ride with 
consumption of the 
carbohydrate-protein 
beverage, when compared 
to the carbohydrate-only 
beverage (P < 0.05). Peak 
post-exercise CK levels 
(12 – 15 hr after the initial 
ride) were significantly 
reduced with ingestion of 
the carbohydrate-protein 
beverage. These findings 
demonstrate significant 
improvements in 
subsequent cycling time to 
exhaustion and reductions 
in muscle damage in 
cyclists with the addition 









Stafford et al., 
2005) 









CHO sports drinks 
during recovery 
from heavy aerobic 
exercise. 
8 (5 females and 
3 males) trained 
endurance 
runners (28.6 + 
6.6 yr, 59.3 + 
8.1 kg, 56.5 + 
5.9 ml/kg/min) 
Subjects performed a 21 
km outdoor run at 70% 
VO2max, followed 
immediately by a run to 
fatigue at 90% VO2max 
on a treadmill. Subjects 
were then administered 
one of three treatments 
during a 2 hour recovery 
period: a carbohydrate 
(8%) and protein (2%) 
beverage, a isocaloric 
10% carbohydrate 
beverage, or a 
commercially available 
6% carbohydrate drink. 
Subjects then performed 
the treadmill run to 
fatigue after 2 hours, and 
were administered the 
same test beverage post-
exercise. The subjects 
finally performed a 5 km 
time trial 24 hours later. 
Subsequent trials were 
performed at least 7 days 
apart with the alternate 
treatment beverages. 
Blood glucose and insulin 
were significantly elevated 
during the 2 hour recovery 
period with ingestion of 
the isocaloric 10% 
carbohydrate beverage (P 
< 0.05). There were no 
significant improvements 
from the first to second 
run to fatigue, or the 24 
hour 5 km time trial with 
all three treatment 
beverages. There were no 
significant differences in 
plasma CK levels in all 
three treatment beverages. 
Muscle soreness ratings 
were significantly lower 
with the carbohydrate-
protein beverage, 
compared to the isocaloric 
10% carbohydrate drink. 
These findings suggest 
that while additional 
calories from carbohydrate 
or protein above those 
provided in commercially 
available drinks do not 
improve subsequent 
endurance performance 
after recovery; the 
additional protein content 











To determine the 
efficacy of 








9 trained male 
cyclists (22.1 + 
2.0 yr, 73.0 + 
4.6 kg, 65.0 + 
9.0 ml/kg/min) 
Subjects performed three 
separate glycogen 
depleting trials at 90, 80, 
70% of their maximal 
power for 2 min 
intervals on the cycle 
ergometry, followed by 
a subsequent 
performance ride to 
exhaustion at 70% 
VO2max after a 4 hr 
recovery. Subjects were 
randomly administered 
isovolumic amounts of 
low-fat chocolate milk, a 
fluid replacement drink, 
or a carbohydrate 
replacement drink 
immediately post-
exercise and at 2 hr into 
the recovery period.  
Subsequent trials were 
performed at least 7 days 
apart with the alternate 
treatment beverages. 
The times to exhaustion 
and total work performed 
in the subsequent ride 
were significantly greater 
with the ingestion of the 
low fat chocolate milk and 
the carbohydrate 
replacement drink, 
compared to the fluid 
replacement beverage (P < 
0.05). There were no 
significant differences in 
heart rate and RPE in the 
subsequent ride, as well as 
in post-exercise blood 
lactate for the glycogen 
depleting exercise and 
subsequent ride among all 
three treatments. These 
findings suggest that 
chocolate milk is an 
effective recovery 
beverage for subsequent 
endurance exercise. 










(Betts et al., 
2007) 









is due to the 
protein content 
itself or from the 
additional calories. 
6 trained male 
endurance 
runners (21 + 3 
yr, 72.6 + 8.4 
kg, 61.4 + 7.3 
ml/kg/min) 
Subjects performed three 
separate trials of 90 min 
treadmill run at 70% 
VO2max. Subjects were 
then administered one of 
three treatments at 30 
min intervals during a 4 
hour recovery period: a 
carbohydrate and whey 
protein isolate beverage, 
a lower carbohydrate 
concentration beverage 
(0.8 g per kg of 
bodyweight), or a higher 
carbohydrate 
concentration beverage 
(1.1 g per kg body 
mass). Following 
recovery, subjects then 
performed a run to 
exhaustion at 70% 
VO2max. Subsequent 
trials were performed at 
least 7 days apart with 
the alternate treatment 
beverages. 
The mean run times to 
exhaustion following the 4 
hour recovery were 
significantly longer with 
the ingestion of the 
carbohydrate-protein 
beverage, and the higher 
carbohydrate dosage drink 
(P = 0.05). The exercise 
capacity during the run 
time to exhaustion was 
significantly improved 
with ingestion of the 
carbohydrate-protein 
beverage, when compared 
with a matched quantity of 
carbohydrate alone (P = 
0.02). There were no 
significant differences in 
time to exhaustion 
between the carbohydrate-
protein beverage and the 
higher carbohydrate 
concentration beverage. 
These findings suggest 
that additional calories 
from protein or 
carbohydrate content in 
recovery beverages 
prolongs time to 
exhaustion and improves 
exercise capacity in 
subsequent endurance 
performance, regardless of 
the origin of the additional 
energy source (sucrose or 











protein (Betts et 
al., 2008) 






two running trials 




(22 + 1 yr, 73.8 
+ 6.7 kg, 61 + 6 
ml/kg/min) 
Subjects performed two 
separate trials of 90 min 
treadmill run at 70% 
VO2max. Subjects were 
then administered either 
a carbohydrate and whey 
protein isolate solution, 
or a carbohydrate-only 
solution at 30 min during 
a  4 hour recovery 
period. Following 
recovery, subjects then 
performed a 60 min 
treadmill run at 70% 
VO2max. The entire 
protocol was repeated 14 
days later with the other 
treatment beverage.  
The serum insulin 
concentrations and median 
insulinemic responses 
were significantly higher 
with the carbohydrate-
protein solution (P = 0.02, 
P = 0.04 respectively). 
Whole-body carbohydrate 
oxidation was 
significantly higher during 
the subsequent run with 
the carbohydrate-protein 
solution (P < 0.01). These 
findings suggest that the 
addition of protein content 
in a carbohydrate recovery 
beverage may increase the 
oxidation of extramuscular 
carbohydrate sources 















(Skillen et al., 
2008) 
To examine the 
two week effects 













12 trained male 
cyclists and tri-
athletes (28.5 + 
2.1 yr; 73.8 + 
4.0 kg and 60.8 




73.6 + 4.1 kg 






Subjects performed a 90 
min cycle ride at 70% 
VO2peak, followed by a 
ride to exhaustion at 
85% VO2max. Subjects 
were then supplemented 
with a 3.6% 
carbohydrate and 1% 
amino acid beverage, or 
a 4.6% isocaloric 
carbohydrate-only 
beverage for 2 weeks. 
Subjects then repeated 
the above cycle rides for 
2 consecutive days after 
the 2 weeks of 
supplementation. The 
entire protocol was 
repeated 14 days later 
with the other treatment 
beverage. 
The time to exhaustion 




only treatment, and 
increased significantly 
with the carbohydrate-
amino acid treatment (P < 
0.05). The decrease in 
vertical jump height on the 
2nd consecutive day was 
significantly attenuated 
with the carbohydrate-
amino acid treatment (P < 
0.05). Plasma CK levels, 
total fatigue score, and 
mood disturbance were 
significantly lower on the 
2nd consecutive day with 
the carbohydrate and 
amino acid beverage.   
These findings suggest 
that the addition of amino 
acids to a carbohydrate 
beverage after consecutive 
day exercise bouts may 
help maintain subsequent 
endurance performance, 
reduce muscle damage, 






















To examine the 








12 trained male 
cyclists (34 + 10 
yr, 75.9 + 4.3 
kg, 4.9 + 0.6 
L/min) 
Subjects performed 3 
high-intensity rides over 
4 days: Day 1 comprised 
of 2.5 hour intervals, and 
days 2 & 4 comprised of 
repeat-sprint 
performances, with day 3 
as a recovery day. 
Subjects were 
administered either the 
protein-enriched diet, or 
the control diet (equal 
servings of protein and 
fat) 4 hours post-exercise 
on days 1 & 2. The entire 
protocol was repeated 14 
days later with the other 
treatment diet. 
The mean sprint power 
was significantly higher 
on day 4 (4.1%, P < 0.05), 
with the protein-enriched 
diet. Overall plasma CK 
levels throughout the 4 
days may experience a 
possible reduction with 
the protein-enriched diet, 
and were substantially 
lower on day 4 before 
exercise (P = 0.08). These 
findings suggest that while 
the addition of protein 
content in a post-recovery 
diet may not confer short-
term (15 hour) benefits, it 
may improve delayed (60 
hour) subsequent high-
intensity sprint 
performance and attenuate 
delayed muscle damage. 
Recovery from a 
cycling time trial 







(Berardi et al., 
2008) 
To examine the 





from a cycling 
time trial on the 
subsequent 60 min 
ride on the same 










(32.43 + 8.85 yr, 
74.76 + 9.39 kg) 
and 8 receiving 
carbohydrate-
only treatment 
(34.00 + 9.74 yr, 
78.98 + 8.21 kg) 
Subjects performed a 
cycle time trial for 60 
min. The distance 
covered was recorded. 
Subjects were then 
administered 1 L of 
carbohydrate-protein or 
carbohydrate only liquid 
supplement at 10/60/120 
min post-exercise. 
Following 6 hours of 
recovery, subjects 
repeated the 60 min cycle 
time trial. 
The decrease in distance 
covered and decrease in 
power output during the 
subsequent time trial were 
significantly reduced in 
the carbohydrate-protein 
supplement group. The 
rate of fat oxidation was 
significantly higher in the 
carbohydrate-protein 
group (P < 0.05), despite a 
higher average workload. 
These findings suggest 
that ingestion of a liquid 
carbohydrate-protein 
supplement post-exercise 
increases fat oxidation, 
increases recovery and 
improves subsequent 
endurance performance in 

























To examine the 








9 trained male 
cyclists (25.4 + 
8.0 yr, 72.8 + 
8.4 kg, 4.3 + 0.4 
L/min) 
Subjects performed three 
separate glycogen 
depleting trials at 90, 80, 
70, and 60% of their 
maximal power for 2 
min intervals on the 
cycle ergometry, 
followed by a subsequent 
performance ride to 
fatigue at 70% maximal 
power after a 4 hr 
recovery. Subjects were 
randomly administered a 
1 g/kg bodyweight of 
carbohydrate 
replacement drink, an 
isovolumic amount of 
fluid replacement drink, 
or an isocaloric amount 
of chocolate milk 
immediately post-
exercise and at 2 hr into 
the recovery period. 
Subsequent trials were 
performed at least 7 days 
apart with the alternate 
treatment beverages. 
The time to exhaustion 
was significantly longer 
with ingestion of the 
chocolate milk, than the 
carbohydrate replacement 
and fluid replacement 
beverages (P < 0.05). This 
finding suggest s that 
when matched for caloric 
content with a 
carbohydrate replacement 
drink, chocolate milk is an 
effective recovery 
beverage for subsequent 
endurance exercise of 


















Table 2.3: Genotypes and Sport Performance. 
Articles Problem/Question 
studied 
Participants Procedures Findings 
Elite endurance 
athletes and the 
ACE I allele – 
the role of genes 
in athletic 
performance 
(Gayagay et al., 
1998) 
To identify genetic 
markers in the 
renin-angiotensin 






(43 males, 21 
females), and 
118 controls 
Blood samples were 
collected and DNA 
extractions were 
performed for  
genotyping analysis of 
the RAS polymorphisms. 
The ACE gene insertion 
(I) and deletion (D) 
polymorphism were 
detected by polymerase 
chain reaction conditions.  
The rowers exhibited 
significantly higher 
frequency of the ACE I 
allele (P > 0.02), and 
significantly higher 
genotypic distributions of 
the homozygous ACE II 
genotype (P = 0.03) than 
the controls. There was a 
corresponding decreased 
frequency of the ACE D 
allele in the rowers. These 
findings suggest that a 
genetic factor associated 
with the ACE I allele may 









(Myerson et al., 
1999) 
To examine the 
frequency 
distribution of the 
ACE I allele in 
elite distance 
runners and other 
elite athletes.   
495 British elite 
athletes: 91 
distance runners 
(48 males, 43 
females), 404 







Subjects‟ DNA were 
extracted from the buccal 
cells contained in 10 ml 
of saline mouthwash 
(0.9% sodium chloride 
solution). The ACE I and 
D polymorphisms were 
identified by polymerase 
chain reaction 
amplification of the 
polymorphic region. 
There is a significant 
linear trend of increasing 
frequency (P = 0.009) in 
the ACE I allele with 
primarily anaerobic 
athletes (< 200 m), mixed 
aerobic and anaerobic 
athletes (400 – 3000 m), 
and primarily aerobic 
athletes (> 5000 m). The 
frequency of the ACE I 
allele was not significantly 
different among the non-
endurance athletes from 
and the 19 disciplines, and 
the controls (P = 0.526). 
These findings show that 
the frequency of the ACE 
I allele is higher in among 
elite distance runners, and 
may increase with the 
distance run. This suggests 
that the ACE I allele is 


















(Yang et al., 
2003) 
To examine the   
effects of the 
ACTN3 genotype 
on human athletic 
performance, and 
determine the 
influence of the 
ACTN3 genotype 
on variations in 
muscle function. 
301 white elite 
athletes: 107 
sprint athletes 







(134 males, and 
292 females). 
Blood samples were 
collected and DNA 
extractions were 
performed for ACTN3 
genotyping. 
There were significant 
differences in allele 
frequencies between sprint 
athletes/endurance athletes 
and controls (P < 0.010). 
The allele frequency 
variations between sprint 
athletes and controls were 
significant for males (P < 
0.001) and females (P < 
0.01). Sprint athletes 
demonstrated a higher 
frequency of the RR 
genotype, a lower 
frequency of the RX 
genotype, and a lower 
frequency of the XX 
(ACTN3 null) genotype, 
while endurance athletes 
exhibited a slightly higher 
frequency of the XX 
genotype than controls. 
There were significant 
differences in allele 
frequencies between sprint 
and endurance athletes in 
both males (P < 0.001) 
and females (P < 0.05). 
This suggests that the R 
allele (ACTN3 positive) 
confers a beneficial effect 
on skeletal muscle 
function in generating 

















differences in elite 
Finnish sprinters 
and endurance 
runners, and to 
assess the potential 
of ACTN3 
genotypes as a 
confounding  
variable. 
141 Finnish elite 
track and field 
athletes: 52 
endurance 
athletes (800m – 
marathon, or 
walking), and 89 
sprinters 
(100/400m or a 
field event). 
Blood samples were 
collected and DNA 
extractions were 
performed for MtDNA 
haplogroup and 
subhaplogroup analyses, 
and ACTN3 genotyping. 
There were significant 
frequency differences in 
mtDNA haplogroups 
between Finnish sprinters 
and endurance runners (P 
= 0.039). The frequencies 
of haplogroups J & K 
were higher in the 
sprinters, whereas the 
frequency of haplogroup I 
was higher in the 
endurance runners. The 
frequency of the ACTN3 
577RR genotype was 
higher in the sprinters, 
whereas the frequency of 
the ACTN3 577XX 
genotype was higher in the 
endurance athletes. The 
577XX genotype was 
inversely correlated to 
best sprint times in the 











cyclists (Lucia et 
al., 2006) 
To examine the 
frequency 
distribution of 
ACTN3 in elite 
cyclists, and 




52 elite male 
Caucasian 
cyclists (26.9 + 
0.4 yr, 178 + 0.8 
cm, 67.4 + 0.9 
kg), 50 elite 
male Caucasian 
endurance 
runners (26.8 + 
0.6 yr, 175.0 + 
0.9 cm, 61.6 + 
0.9 kg), and 123 
sedentary 
Caucasian males 
(19 – 50 yr). 
Gas-exchange 
measurements were 
obtained for the cyclists 
and runners, from 
maximal exercise tests to 
fatigue on the cycle 
ergometer and treadmill 
respectively, as indices of 
endurance performance. 
Blood samples were 
taken for DNA extraction 
and ACTN3 genotyping 
analysis (RR, RX, and 
XX). 
There were no significant 
differences among elite 
cyclists, elite runners, and 
sedentary controls in all 
three ACTN3 genotype 
distributions (P > 0.05). 
There was a trend for a 
higher frequency of the 
ACTN3 XX genotype in 
elite cyclists. There were 
no significant differences 
between elite cyclists and 
elite runners of each 
genotype in the indices of 
endurance performance: 
VO2max, ventilatory 
threshold (VT), and 
respiratory compensation 
threshold (RCT). This 
suggests that the ACTN3 
polymorphisms do not 
confer advantages in 
endurance performances. 






(Norman et al., 
2008) 





(mAMPD), due to 
variations in the 
AMPD1 gene, 
affect blood flow 
response to high 
intensity exercise. 
15 subjects (21 
– 32 yr) 
Subjects perform a 30s 
Wingate test against a 
workload of 7.5% of 
body weight. Peak and 
average power over 5-s 
periods, mean power 
over entire 30-s duration, 
and power decline were 
recorded. Common 
femoral artery blood flow 
velocity and vessel 
diameter were measured 
pre- and 25 min post-
exercise. Blood samples 
were collected 
1/3/6/9/12/18/25 min 
following exercise.  
Subjects homozygous and 
heterozygous for AMPD1 
34C>T alleles MM/NM 
demonstrated significantly 
lower mean power than 
subjects homozygous for 
the AMPD1 normal allele 
NN (7.7 ± 0.6 W/kg vs 8.7 
± 0.2 W/kg, P < 0.01) as 
well as lower peak power, 
and larger power declines. 
MM/NM subjects 
demonstrated a 
significantly higher peak 
femoral arterial blood 
flow than NN subjects 
(5.44 ± 0.41 l/min vs 4.10 
± 0.31 l/min, P < 0.001), 
and a significantly faster 
normalization of arterial 
blood flow post-exercise 
(7.8 ± 1.1 min, vs 16.1 ± 
1.4 min, P < 0.001). This 
was associated with a 
faster heart rate recovery 
in MM/NM subjects post-
exercise. This suggests 
AMPD1 mutations 
contribute to diminished 
mAMPD, which would 
result in greater adenosine 
accumulation, thereby 
promoting exercise-
induced hyperaemia in 




















To examine the 
mechanisms by 







analysis of the 
biochemical and 
physiological 




9 wk), 43 males 
(19 wild-type, 






Grip strength was 
measured. Body 
composition was 
determined by DEXA.  
Transverse sections 
of the quadriceps, 
spinalis thoracis, 
extensor digitorum 
longus (EDL), and soleus 
muscles were analyzed 
for fiber type proportions 
and measured for size. 
Mitochondrial enzyme 
levels were measured to 
examine muscle 
metabolic activity. Fast-
twitch EDL muscles 
were isolated to examine 
differences in contractile 
properties.  
Average grip strength was 
significantly lower in 
knockout mice than wild-
type mice (P = 0.007 
males, P = 0.02 females). 
Total body weight was 
lower in male and female 
knockout mice than the 
wild-type mice. This was 
attributed to loss of lean 
mass rather than loss of fat 
mass. Fast glycolytic type 
IIb fibers responsible for 
ACTN3 in wild-type mice 
were significantly smaller 
in the quadriceps (P < 
0.05), and spinalis (P < 
0.01) of knockout mice. 
There were no significant 
differences in the total 
number of fibers in the 
EDL. This suggests that 
the reduction in muscle 
mass in knockout mice 
was attributed to reduction 
in specific fiber size rather 
than differences in fiber 
type distributions. The 
metabolic profile of 
knockout mice exhibited 
increases for enzymes in 
the glycolytic pathway, 
mitochondrial enzymes of 
the tricarboxylic acid 
cycle, electron transport 
chain enzyme, and 
mitochondrial enzymes 
involved in fatty acid 
oxidation. These changes 
in muscle metabolism 
suggest that in the absence 
of ACTN3, there is a shift 
from anaerobic towards 
aerobic pathways, as well 
as an increased reliance in 
B-oxidation of fatty acids. 
The twitch half-relaxation 
times in fast-twitch EDL 
muscles were significantly 
longer in knockout mice 
than wild-type mice (P = 
0.007), and recovery from 
fatigue induction as 
determined by force 
generation capacity was 
greater in knockout mice 
muscle. These changes in 
contractile properties 
suggest a shift in the 
characteristics of fast 
fibers towards slow fibers 









(Eynon et al., 
2009) 
To examine the 
frequency 







sports (sprints and 
endurance events) 
at different levels 
of competition (top 
and national level) 
among the athletic 
Israeli population.  
155 athletes 
(35.9 + 12.2 yr), 
119 males and 
36 females, 74 
distance runners 
(20 top level, 54 
national level) 
and 81 sprinters 
(26 top level, 55 
national level). 
240 controls, 
170 males and 
70 females.  
Genomic DNA was 
extracted from peripheral 
blood leukocytes for 
genotyping of the 
ACTN3 R577X 
polymorphism  
The ACTN3 R577X 
genotype and allele 
frequencies were 
significantly different 
between sprinters and 
distance runners (P = 
0.00009, and P = 0.00007 
respectively), and between 
sprinters and controls (P = 
0.00003, and P = 0.00002 
respectively). The 
genotype frequencies were 
significantly different 
between the distance 
runners and controls, 
while the differences in 
allele frequencies between 
distance runners and 
controls demonstrated a 
trend towards significance 
(P = 0.08). Distance 
runners exhibited a 
significantly higher 
proportion of the XX 
genotype than sprinters (P 
= 0.005), and controls (P = 
0.006). The R allele was 
more frequent in top level 
sprinters than national 
level sprinters. This 
suggests that ACTN3 R 
allele may be associated 
with top level sprint 
performance. There were 
no significant differences 
in genotype and allele 
frequencies in top level 
and national level 
endurance athletes (P = 
0.7). This suggests that the 
ACTN3 X allele and XX 
genotypes may be additive 
rather than critical to 












Table 2.4: Genotypes and Muscle Performance.  
Articles Problem/Question 
studied 










(Folland et al., 
2000) 
To examine the 
effect of the ACE-
D allele on the 
response of human 




33 males (21.4 ± 
0.5 yr, 75.9 ± 
2.1 kg, 180 ± 1 
cm) body mass 
index, 23.3 ± 
0.6 kg/m2) 
Subjects participated in a 
9-week strength training 
program of the 
quadriceps muscle, with 
each leg randomly 
assigned to isometric or 
dynamic strength 
training. Epithelial cells 
were collected through 




strength (MVC) of the 
quadriceps muscle was 
measured. Additional 
strength measurements 
include peak isokinetic 
torque at four angles and 
three velocities 
Subjects with the ACE-D 
allele demonstrated 
significant improvements 
in quadriceps muscle 
strength (MVC) with 
isometric strength training 
(P < 0.05), and 
demonstrated a trend for 




training and genotype was 
non-significant with 
dynamic strength training. 
The interaction between 
genotype and training was 
consistent in all strength 
measurements for both 
types of training (ACE ID 
> ACE DD > ACE II). 
This suggests that the 
renin-angiotensin system 
may play a role in the 
response of skeletal 
muscle to functional 
overload via the ACE ID 
polymorphism. 
The ACE gene 
and muscle 
performance 





genotypes and  








(19.4  0.3 yr, 
1.78  0.01 m, 
71.3  1.2 kg) 
Subjects participated in a 
primarily aerobic 11-
week physical training 
program. Blood samples 




training steady state 
oxygen uptake (VO2) and 
respiratory exchange 
ratio (RER) were 
measured on a cycle 
ergometer exercise to 
determine the efficiency 
of muscular contraction 
(delta efficiency). 
Baseline delta efficiency 
was independent of ACE 
genotypes (P = 0.59). 
Subjects homozygous for 
ACE II genotype 
documented significantly 
higher post-training delta 
efficiency than baseline (P 
< 0.01), and significantly 
higher increases in delta 
efficiency than subjects 
homozygous for ACE DD 
genotype (P < 0.025). This 
suggests that the ACE II 
genotype may be 
associated with an 
improved mechanical 
efficiency in trained 
skeletal muscles due to 
possible increases in slow-
twitch muscle fibers, 
which are more efficient 








The I allele of 
the angiotensin-
converting 





I fibers in human 
skeletal muscle 
(Zhang et al., 
2003) 










females,  24 ± 3 
yr) 
Blood samples were 
taken for DNA extraction 
and genotyping analysis. 
Skeletal muscle samples 
were taken from the left 
vastus lateralis, and fiber 
type distribution was 
classified into type I, IIa 
and IIb.  
Subjects homozygous for 
ACE II genotype 
exhibited significantly 
higher percentages of type 
I fibers, and significantly 
lower percentages of type 
IIb fibers compared with 
subjects homozygous for 
ACE DD genotype. 
Across the genotype 
groups, there are 
significant linear trends (P 
< 0.01) for decreased 
distribution of type I fibers 
(ACE II > ACE ID > ACE 
DD), and increased 
distribution of type IIb 
fibers (ACE II < ACE ID 
< ACE DD). This 
demonstrated that the 
ACE-I allele is associated 











(Clarkson et al., 
2005) 
To determine the 
associations 
between ACTN3 







602 subjects (18 
– 40 yr), 247 







Subjects participated in a 
12-week resistance 
training program of their 
non-dominant elbow 
flexor/extensor. Blood 
samples were taken for 




isometric (MVC) and 
dynamic (1-RM) 
strength, and muscle size 
(cross-section area) of 
the elbow flexor were 
measured.  
No significance between 
ACTN3 genotype and 
muscle size/strength in 
male subjects. Female 
subjects homozygous for 
the mutant ACTN3 XX 
allele exhibited 
significantly larger gains 
in absolute and relative 1-
RM (P < 0.05). ACTN3 
genotype is associated 
with 2% of baseline MVC 
and 1-RM strength gain (P 
= 0.01). This suggests 
ACTN3 may contribute to 
genetic variations in 
muscle response and 


























ACE insertion (I) 
and deletion (D) 
polymorphisms 





(24.2  + 0.2 yr), 
264 (41.8%) 









Subject participated in a 
12-week unilateral upper-
arm resistance training 
program of their non-
dominant arms (5 
exercises: bicep preacher 
curl, biceps concentration 
curl, standing biceps curl, 
overhead triceps 
extension, and triceps 
kickback). Exercise 
intensity started at 65 – 
75% of 1-RM (3 sets x 
25 repetitions), and was 
increased at week 5 (75 – 
82% 1-RM, 3 sets x 8 
repetitions) and week 10 
(83 – 90% 1RM, 3 sets x 
6 reps). Blood samples 





isometric (MVC) and 
dynamic (1-RM) 
strength, and muscle size 
(cross-section area) of 
the elbow flexor were 
measured. 
Absolute and relative 
MVC increases were 
greater for ACE II/ID 
genotypes than ACE DD 
genotype in non-
dominant/trained arms (P 
< 0.05), as well as 
dominant /untrained arms 
(P < 0.05) post-training. 
Absolute and relative 
increases in 1-RM and 
cross-section area were 
independent of ACE 
genotype groups in non-
dominant arms post-
training (P >or = 0.05).  
Absolute and relative 
increases in 1-RM and 
cross-section area were 
greater for ACE DD/ID 
genotypes than ACE II 
homozygotes in dominant 
arms post-training (P < 
0.05). There were no 
differences in baseline 
muscle strength and size 
among the ACE genotype 
groups. This suggests that 
the ACE ID genotype may 
be more associated with 
the contralateral education 
and learning effects of 
unilateral resistance 
training, than with 








(Vincent et al., 
2007) 









90 males (21.7 + 
2.3 yr, 73.3 + 
8.6 kg) 
Blood samples were 
taken for DNA extraction 
and genotyping analysis. 
Isometric knee extensor 
strength (45°) was 
measured at different 
dynamic velocities (100 
– 300°/s). Skeletal 
muscle samples were 
taken from the right 
vastus lateralis, and fiber 
type distribution was 
classified into type I, IIa 
and IIx. Protein content 
in the different fiber 
types was determined 
with assays. 
Subjects homozygous for 
the ACTN3-R allele 
recorded significantly 
higher relative dynamic 
quadriceps torques at 
300°/s, compared with 
subjects homozygous for 
XX (P < 0.05). Subjects 
homozygous for RR 
exhibited significantly 
greater distribution of type 
IIx fibers than subject 
homozygous for XX (P < 
0.05). -actinin-3 protein 
content was higher in type 
IIx than in type IIa fibers. 
This suggests the 
differences in skeletal 
muscle fiber type 
characteristics between the 
two ACTN3 genotype 
groups are significant, and 
the association between 
the ACTN3 polymorphism 
and fiber type distribution 




















to strength training 
in older adults.  
243 subject (50 





Americans   
Subjects participated in a 
10-week unilateral knee 
extension training of 
their dominant leg. Blood 
samples were taken for 
DNA extraction and 
genotyping analysis. 
Baseline and post-
training muscle strength 
of the knee extensor (1-
RM) and quadriceps 
muscle volume (MV) 
were measured. 
Baseline MV in subjects 
homozygous for ACE DD 
genotype was significantly 
greater in both trained (P 
= 0.02) and untrained legs 
(P = 0.01) than subjects 
homozygous for ACE II 
genotype. There were no 
significant differences in 
baseline 1-RM in both 
trained and untrained legs 
among the ACE genotype 
groups. Post-training 1-
RM (P < 0.01) and MV (P 
< 0.01) improved 
significantly among all 
ACE genotype groups, 
and there were no 
genotype differences in 
post-training 1-RM and 
MV in both legs. This 
suggests that there is no 
association among the 
ACE genotype groups for 
muscle strength and 
muscle volume 
adaptations to strength 
training in older adults, 
and that the ACE 
genotype is more 
associated with baseline 







strength in elite 
athletes  
(Costa et al., 
2009) 






strength in elite 
male and female 
athletes.  
58 elite athletes: 
35 swimmers 
(19 males, 16 
females, 18.8 ± 
3.2 yr), 23 tri-
athletes (15 
males, 8 female, 





either as short 
(< 200m), or 
middle (400m – 
1500m) distance 
athletes 
 Baseline blood samples 
were collected for DNA 
extraction and ACE 
genotyping. Baseline 
bilateral grip strength, 
and maximum height in 
squat jump and counter 
movement jump were 
recorded. 
Male and female subjects 
homozygous for ACE DD 
alleles demonstrated 
significantly higher right 
grip strength (P < 0.05) 
compared to subjects 
homozygous to ACE II 
allele. Short distance 
subjects of both genders 
recorded higher scores in 
most strength 
measurements (P <0.05) 
than middle distance 
subjects. Female subjects 
heterozygous for ACE ID 
allele recorded 
significantly higher right 
grip strength (P = 0.032) 
and counter movement 
jump (P = 0.048) than 
those homozygous for 
ACE II allele. This 
suggests that ACE D allele 
is associated with baseline 
muscle strength in elite 







Table 2.5: Genotypes and skeletal muscle damage/recovery. 
Articles Problem/Question 
studied 












To examine the 
time course 
between increases 








rats (205 + 3 g). 
60 rats were 
hypophysectomized to 
reduce circulating IGF-1 
and GH. The normal and 
hypophysectomized rats 
were grouped into 
overload and control 
groups. Bilateral removal 
of the gastrocnemius and 
soleus muscles was 
performed to overload 
the plantaris muscles in 
the overload groups. At 
3/7/14/28 days post-
surgery, control and 
overloaded rats were 
killed with an overdose 
of pentabarbitol sodium. 
Plant muscles from both 
legs were excised for 
subsequent analysis. 
Peak muscle IGF-1 
peptide levels in normal/ 
hypophysectomized rats 
occurred after 3/7 days of 
overloading, and were 
demonstrated a 4.1/6.2-
fold increase against 
controls. These increases 
in muscle IGF-1 preceded 
the following hypertrophic 
response: Plantaris mass, 
myofiber size, and protein 
to bodyweight ratio were 
significantly higher with 
overloading in normal and 
hypophysectomized rats 
than the control groups (P 
< 0.05). The total DNA 
content of the plantaris 
muscles increased 
significantly in normal 
and hypophysectomized 
rats with overloading. The 
relationship between IGF-
1 peptide levels and total 
DNA content in the 
plantaris muscle was 
significant in normal (r = 
0.53, P = 0.0001) and 
hypophysectomized (r = 
0.73, P > 0.0001) rats with 
overloading. These 
findings suggest that rats 
with normal and severely 
attuenated levels of IGF-1 
increase their expression 
of local IGF-1 as a 
response to functional 
overload, which may 
contribute to the muscle 
hypertrophy response, 
through mobilization of 
satellite cells to provide 
















(Gerrard et al., 
1998) 
To examine the 








three 21 day old 
neonatal pigs, 
and three 6 
month-old adult 
pigs. 
Muscle and tissue 
samples were obtained 
from the semi-tendinosus 
of a limb and liver 
respectively for mRNA 
analysis. Muscle samples 
were taken from the 
contralateral pelvic limb 
for in situ hybridization. 
Peak levels of muscle 
IGF-II occurred in 59 day 
old porcine fetuses and 
declined thereafter (P < 
0.05). Maximal levels of 
muscle IGF-I occurred 
around birth (P < 0.05). 
Expression of IGF-I and 
IGF-II mRNA was 
localized to developing 
muscle fibers, as there was 
little signal was found in 
the surrounding 
connective tissues. These 
findings suggest that  
IGF-I and -II are primarily 
expressed and produced in 
muscle cells within 
developing muscle tissue, 











To examine the 
effects of repeated 
cycles of atrophy 
and re-growth on 
the capacity of 
satellite cells to 







(FBN) male rats 
(3/8/31 mo) 
were used to 
determine the 
effects of 




FBN male rats 
(25 – 26 mo, 
523 + 10 g) 








Muscle samples were 
obtained from the 
gastrocnemius in the hind 
limbs bilaterally to 
isolate and culture 
satellite cells. Three 
cycles of  hind-limb 
immobilization with 
plaster casts and 
intervening recovery 
periods were 
administered to promote 
atrophy and re-growth in 
skeletal muscle. 
 
There were significant 
losses in gastrocnemius 
muscle mass and in the 
proliferative potential of 
the resident satellite cells 
after one bout of 
immobilization (P <  
0.05), both of which did 
not recover from their 
decreased levels after 
either the first 3-week or 
subsequent 9-week 
recovery period. The 
infusion of IGF-I onto the 
atrophied gastrocnemius 
muscle for two additional 
weeks after the 9-wk 
recovery period rescued 
46% of the lost muscle 
mass and significantly 
increased proliferation 
potential of the satellite 
cells (P <  0.05). These 
findings demonstrate the 
beneficial effects of local 
infusion of IGF-I to 
activate satellite cells in 


















(Hameed et al., 
2003) 
To examine the 
acute effects of 
resistance 
weightlifting 






8 young men 
(29.5 ± 1.5 yr, 
81.1 ± 2.4 kg, 
179.3 ± 1.8 cm), 
and 7 elderly 
men (74.4 ± 1.8 
yr, 74.7 ± 2.1kg, 
177 ± 2.3 cm) 
Subjects performed 10 
sets of 6 repetitions of 
single-leg knee extensor 
exercise at 80 % of their 
1-RM. Muscle biopsy 
samples were taken from 
the vastus laterialis of the 
test leg and control leg 
2.5 hr post-exercise. 
Total RNA was extracted 
from both test and 
control muscle samples, 
and transcribed into 
cDNA. mRNA was 
coded for ACTN, IGF-
IEa, IGF-IEc (MGF) and 
MyoD. 
Resting levels of IGF-IEa 
mRNA were significantly 
higher than MGF mRNA.   
There were no differences 
in resting levels of MGF 
mRNA and IGF-IEa 
mRNA between the young 
and elderly subjects. The 
resting levels of MyoD 
mRNA were significantly 
higher in the elderly 
subjects. With resistance 
exercise, the levels of 
MGF mRNA were 
significantly higher in the 
exercised legs than control 
legs of the younger 
subjects, but not the 
elderly subjects. There 
were no significant 
differences in the levels of 
IGF-IEA mRNA and 
MyoD mRNA between 
the control and exercised 
legs in both subject groups 
with resistance exercise. 
The proportion of myosin 
heavy chain II (MHC-II) 
were significantly lower 
(P < 0.05) in the 
quadriceps of the elderly 
adults. These findings 
suggest that resistance 
training attenuate the 
MGF response in elderly 
adults, whereas MGF and 
IGF-IEa isoforms are 
regulated differentially in 
young skeletal muscle. 







(Koh et al., 
2005) 
To examine the 
role of the 
plasminogen 
system in skeletal 
muscle regulation 
and regeneration, 
and specifically, to 
test if deficiency in 
plasminogen 
activator inhibitor-








uPA and PAI-1 
null mice 
Mice were anesthetized 
and isometric force 
measurements were 
recorded in situ. 10 ul of 
cardiotoxin was injected 
into three locations of the 
extensor digitorum 
longus muscle. Mice 
were allowed to recover, 
and isometric force 
measurements were 
recorded 1 – 20 days post 
injection.   
PAI-1 null mice exhibited 
greater expression of 
MyoD and developmental 
protein, and more rapid 
recovery of muscle 
morphology, protein 
levels, and function post-
treatment compared to 
wild-type mice. The 
accelerated rate of 
recovery in PAI-1 mice is 
associated with greater 
accumulation of 
macrophages post-
treatment. This suggests 
inhibition of PAI-1 in 
mice attenuates 
plasminogen activator 












(Clarkson et al., 
2005) 
To examine if 
variations in the 
genes coding for 
myofibrillar 
proteins involved 








(age of 24.1 ± 
5.2 yr, height of 
170.8 ± 9.9 cm, 
body mass of 
73.3 ± 17.0 kg), 








Subjects performed 50 
maximal eccentric elbow 
flexor contractions (2 
sets x 25 repetitions, 5 
min interval). Maximal 
isometric strength 
(MVC) was tested pre- 
and immediately post-
exercise and 4/7/10 days 
post-exercise. Blood 
samples were taken pre- 
and 4/7/10 days post-
exercise for CK and Mb 
analysis, as well as DNA 
extraction and 
genotyping 
ACTN3 R577X is 
associated with baseline 
CK activity, and explained 
3.5% of all variation 
within baseline CK 
activity; no association 
with change in 
strength/blood proteins 
post exercise.  
MLCK 49T (homozygous 
rare allele found in 3.9% 
of subjects): greater 
increases in CK (28,934 
U/l) and Mb (937 ng/ml). 
MLCK C37885A 
(heterozygous rare allele 
found in 22.3% of 
subjects): 57% strength 








(Yamin et al., 
2007) 
To determine the 




the ACE ID 





exercise.   
70 physical 
education 
students (25 ± 3 
yr, 171 ± 8 cm, 
67 ± 10kg), 42 
males and 28 
females 
 
Subjects performed 1 set 
of 50 maximal eccentric 
elbow flexor contraction 
of their non-dominant 
arm. Blood samples were 
taken pre- and 
3/24/48/72/96/120/168 hr 
post-exercise for CK 
activity and genotype 
analysis 
The ACE ID genotype 
was the most powerful 
independent determinant 
of peak CK activity (95% 
confidence interval, P = 
0.02). The homozygous 
ACE II allele was 
associated with the highest 
peak CK activity (8,882 ± 
2,361 U/l) and the largest 
increase in CK activity 
(8,735 ± 2,352 U/l). Peak 
CK activity and increases 
in CK activity were 
intermediate in the 
heterozygous ACE ID 
allele (4,454 ± 1,105 U/l, 
4,296 ± 1,108 U/l), and 
lowest in the homozygous 
ACE DD allele (2,937 ± 
753 U/L, 2,778 ± 757 U/l). 
This suggests that the 
ACE II genotype may be 
associated with the 
development of exertional 
rhabdomyolysis, whereas 
the ACE DD genotype 


















(Devaney et al., 
2007) 







151 subjects -  
73 males (25.3 ± 
5.4 yr, 170.5 ± 
7.9 cm, 81.9 ± 
17.2 kg) and 78 
females (22.8 ± 
4.6 yr, 159.2 ± 
6.8 cm, 64.5 ± 







Subjects performed 50 
maximal eccentric elbow 
flexor contractions (2 
sets x 25 repetitions, 5 
min interval). Maximal 
isometric strength 
(MVC) was tested pre- 
and immediately post-
exercise as the criterion 
measure. Muscle 
soreness was assessed 
pre and 3/4/7/10 days 
post-exercise via a visual 
analog scale. Blood 
samples were taken pre- 
and 4/7/10 days post-
exercise for CK and Mb 




(homozygous rare allele 
found in 18.6% of 
subjects): 58% strength 
loss immediately post-
exercise, increased serum 
CK activity at 7 days post-
exercise (8818 U/l).  
IGF-II G17200A 
(homozygous rare allele 
found in 11.0% of 
subjects): 60% strength 
loss immediately post-
exercise, increased CK 
activity at 7 days post-
exercise (12261 U/l). 
IGF2AS A1364C 
(homozygous wild type 
found in 36.2% of 
subjects): 58% strength 
loss, 50mm soreness. 
IGF2AS G11711T 
(homozygous wild type 
found in 27.8% of 
subjects): 56% strength 
loss, 56mm soreness, 
increase in blood CK 



































 Fourteen endurance-trained male cyclists (18-45 yrs) were recruited from James 
Madison University and the surrounding area. The inclusion criteria included a minimum 
of three days a week of cycling for the past 2 months, and a peak aerobic capacity 
(VO2peak) greater than 45 ml/kg/min. All subjects received a written consent form that 
described the risks and benefits associated with the study. After a description of the 
protocols, subjects signed the written consent form. James Madison University 




The study design consisted of a pre-testing/screening phase, familiarization trial, 




All potential subjects that met the study criteria completed the following 
assessments.   
Body Mass and Height 
 
Subjects had their body weight measured to the nearest 0.1kg and height 
measured to the nearest 0.5cm. 
VO2peak/Wmax 
 
Subjects completed an exercise test to determine their peak oxygen uptake 





a cycle ergometer at a self-selected pace, described as a “comfortable but not easy 
pace for an hour long ride.” After subjects selected their initial workload, power 
output was increased by 25 W every 2 minutes until the subject voluntary 
requested to stop the test due to fatigue. Peak oxygen uptake and power output 
were measured during the test to determine if subjects met entry criteria for the 
study, and to establish intensities for subsequent exercise protocols.   
 
Familiarization Trial 
All subjects that met the inclusion criteria performed a familiarization trial within 
two weeks of the pre-testing assessment. The purpose of the familiarization trial was to 
determine if the exercise intensities were appropriate for each subject. The familiarization 
trial also allowed subjects to become acclimated to the protocol and establish the 
appropriate pace for the time-trial segment. Subjects were tested prior to the treatment 
phase in order to alter workloads and to ensure they can complete the treatment trial. 
Another purpose of the familiarization trial was to minimize any effects of learning and 
the repeated-bout effect, in order to reduce error variance between treatment trials. All 
subjects received the CHO recovery beverage during the familiarization trial (described 
below). The treatment phases began 7 to 10 days following the familiarization trial. No 
blood draws or muscle recovery measures were taken during the familiarization trial. 
 
Treatment Phases 
Treatment phases were similar to the familiarization trial with the addition of the 





muscle recovery measures. The treatment phase consisted of a glycogen-depleting 
exercise, a recovery period and a subsequent time trial.  
A visual timeline of events during each of the treatment phase is provided in 
Figure 3.1 below. 
 
Figure 3.1: Timeline for exercise trials and measurements of recovery. 
 
PRE:              Post:   0.5HrPost:   2HrPost:  4HrPost:    Post:   24HrPost: 
MS MVC   IN         TB         MS MVC MS 
MPEF TB   GL          MPEF TB MPEF 
CK               MVC       CK 
MVC      MVC  
           4 hours 
      
                                                                                    
         24 hours 
 
MS=Muscle Soreness, MPEF= Mental/Physical Energy/Fatigue, CK=Creatine Kinase,  




Subjects performed a steady state warm-up for 10 minute at 60% Wmax. After the 
initial 10 minutes of exercise, subjects completed a series of 2 minute high-
intensity intervals. The high-intensity intervals consisted of 2 minutes at 95% 
Wmax at a cadence of 70 rpm, followed by 2 minutes at 50% Wmax. Once the 
cadence dropped below 70 rpm, the workloads for the high-intensity intervals 
were decreased to 85% Wmax, with the cadence remaining at 70 rpm. Once the 
cadence dropped below 70 rpm again, the workload for the high-intensity 
intervals was further decreased to 75% Wmax. The test was terminated when 
subjects failed to maintain a cadence of 70 rpm at this intensity. This protocol was 
designed to induce muscle glycogen depletion and moderate fatigue (Kuipers et 
al., 1987). Based on similar findings from Karp et al (2006) and Van Loon et al 
Subsequent 
Exercise 








(2000), the duration of the test was expected to last approximately 50-75 minutes, 
with 30-45 minutes of high-intensity intervals. All subjects were permitted to 
consume water ad libitum throughout the trial.  
 
Recovery Period 
Following the glycogen-depleting exercise there was a 4 hour period of recovery. 
Subjects consumed 750 ml of a recovery beverage immediately following this 
trial and again 2-hours post-exercise (see „treatment beverage‟ below for 
description).  
 
Subsequent Exercise Performance 
After a 4 hour recovery period, subjects performed an endurance performance 
trial on a computerized cycle ergometer (VeloTron, Racermate, Inc). The start of 
the trial consisted of 20 minutes at a steady-state pace, with intensity 
corresponding to 60% Wmax. The purpose of the steady state segment was to 
assess steady-state substrate utilization, and to ensure depletion of muscle 
glycogen. Following 20 minutes of steady-state exercise, subjects completed a 
simulated 20 km time trial. The last 5 km of the course consisted an uphill 
segment at 5% elevation. This was included in the protocol to allow an 
assessment of late-exercise performance. 
All trials were performed at ambient room temperature (70-72
 o
F). The subjects 
were asked to void their bladders prior to all trials. A Windmere fan, set on 
„medium‟ speed, was placed 2 meters from the handlebars of the ergometer for 





trials. Each subject was asked to provide maximal effort and treat each time trial 
as a competitive event. For consistency, no verbal encouragement was provided to 
the subjects during the time trial. The only feedback subjects received during the 
trials regarding performance were distance remaining and distance completed.  
Subjects were given at least one week between trials to ensure complete recovery. 
Participants were allotted 14 days to complete a trial in the event of unrelated 




Subsequent Exercise Performance 
 
 Exercise performance was measured using cycling time to completion for the 20 
km time trial. Time was also recorded during the final 5km of the course.  
 
Physiological Responses during Steady-State Exercise 
Metabolic Measurements 
 
Metabolic measurements were obtained during the glycogen-depleting trial and 
during the steady-state segment of the subsequent performance trial using a 
SensorMedics Spectra metabolic cart. These measurements were obtained after 3 
minutes of cycling during the glycogen depleting trial (at 60% Wmax) and after 3 
minutes of cycling during the subsequent performance trial (also at 60% Wmax). 
Expired respiratory gases were collected for 5 minutes at each time point. 
Average values were calculated using the final 3 minutes of each time period, 





expired gases included oxygen uptake (VO2), ventilation (VE), and respiratory 
exchange ratio (RER).  
 
Blood Glucose and Lactic Acid 
 
Blood samples were obtained immediately prior to exercise, during the glycogen-
depleting trial (at minute 8) and exercise performance trial (at minute 8), and 30 
minutes post-exercise. Approximately 0.5 ml of blood was collected during each 
point via a finger-stick. An automated analyzer (YSI 2300 STAT glucose/lactate 




Thirty minutes after consuming the recovery beverage, 5 ml of blood was 
collected using a venous blood draw from an antecubital vein. The blood was 
collected in SST clot agent Vacutainer
®
 tubes, centrifuged, and serum stored at -
80
 o
C. Insulin levels were assessed from the serum through a commercially-




Heart rate was recorded using a Polar heart rate monitor (Lake Success, NY). 
Measurements were obtained at minute 8 of the glycogen-depleting trial and the 
subsequent exercise trial. Average heart was also recorded for the 20 km time trial 










Ratings of Perceived Exertion (RPE) 
 
Ratings of perceived exertion were obtained by having the subjects point to a 
corresponding level of exertion on the Borg RPE scale (6-20). The RPE recording 
was collected at the 8 minute mark during the glycogen-depleting and subsequent 
exercise. The following statement was read to the subjects to explain the RPE 
scale: “Please describe your current level of exertion using the following scale. 
This level should represent your overall perception of effort, and not localized to 
a specific group of muscles, etc. For reference, a 6 would represent your effort 
when you are resting or watching TV, while 20 would represent the highest level 
of exertion you are capable of producing during exercise”. 
 
Muscle Recovery Variables 
 
Muscle recovery variables included ratings of muscle soreness, mental and 
physical energy/fatigue ratings, isometric peak torque (MVC), and serum creatine kinase 
(CK). Muscle soreness ratings and mental/physical energy/fatigue ratings were collected 
during the following three time points; prior to the glycogen depletion trial (PRE), prior 
to the subsequent exercise performance trial (4HrPost) and 24 hours following the 
glycogen depletion trial (24HrPost). Serum CK was obtained twice: PRE and 24HrPost. 
Peak MVC was assessed five times: PRE, 4HrPost, 24HrPost, as well as immediately 
after the glycogen depleting trial and subsequent trial. A visual timeline of the muscle 








Serum Creatine Kinase (CK) 
Serum CK was measured as an indirect indicator of muscle damage. 
Approximately 5ml of blood were obtained using a venous blood draw from an 
antecubital vein prior to exercise and 24-hr post exercise. Using a centrifuge, 
whole blood was spun at 7000 rpm to separate serum and stored in a -80
 o
 C 
freezer. Serum CK was analyzed using a Johnson and Johnson Vitro DT6011. The 
measurement device was calibrated prior to analyses using a reconstituted 
lyophilized calibration standard purchased from the manufacturer. 
 
Muscle Function Test/Isometric peak torque (MVC) 
 
Peak torque of the knee extensors were assessed to determine treatment 
differences in muscle function during recovery from exercise. Subjects were 
seated in a modified leg extension chair and asked to push as hard as possible 
against a shin pad that was connected to a force transducer. Each subject 
performed 3 to 6, 5-second repetitions at each time-point. There was a 1 minute 
rest between each repetition. MVC was also assessed immediately following both 
exercise sessions. 
 
Mental and Physical Energy/Fatigue Ratings 
 
The Mental and Physical State and Trait Energy and Fatigue Scales (MPSTEFS, 
O‟Conner, 2004) were used to record ratings of mental and physical energy. 
Separate ratings of physical energy, physical fatigue, mental energy and mental 
fatigue were obtained using visual analog scales, with potential scores ranging 





Muscle Soreness Ratings 
 
During the familiarization trial subjects received instruction on how to utilize the 
muscle soreness scale. The following statement was read to the subjects; “please 
describe your overall level of muscle soreness that you feel currently while 
performing normal daily activities (i.e. walking up or down stairs)”. The soreness 
rating used a 100mm visual analog scale; 0 indicated no muscle soreness and 100 
indicated impaired movement due to muscle soreness.  
 
Genotyping 
Single nucleotide polymorphisms (SNPs) were evaluated in this study to 
determine if specific variations in these polymorphisms were associated with variations 
in muscle recovery variables, and examine their influence on individual responses to 
recovery beverages with protein. The following SNPs were evaluated in this study: 
ACTN3 R577X, IGF-II C13790G, IGF-II G17200A, IGF2AS A1364C, and IGF2AS 
G11711T. Approximately 4 ml of blood were obtained using a venous blood draw from 
an antecubital vein prior to the glycogen depleting exercise during the first trial, and 
mixed through inversion. DNA was isolated from each blood sample using the QIAamp® 
DNA Blood Mini Kit (Qiagen, CA). Subject identification information was removed for 
all DNA samples, which were subsequently shipped to the Research Center for Genetic 
Medicine at the Children‟s National Medical Center in Washington D.C. for genotyping. 
The following genotype polymorphisms were selected for genotyping based on 
their susceptibility to impaired muscle recovery as demonstrated by increased serum CK 
levels, strength loss, and muscle soreness following eccentric resistance exercises in prior 





1) IGF-II C13790G (homozygous rare allele found in 18.6% of subjects): 58% 
strength loss immediately post-exercise, increased serum CK activity at 7 days 
post-exercise (8818 U/l) (Devaney et al., 2007). 
2) IGF-II G17200A (homozygous rare allele found in 11.0% of subjects): 60% 
strength loss immediately post-exercise, increased CK activity at 7 days post-
exercise (12261 U/l) (Devaney et al., 2007). 
3) IGF2AS A1364C (homozygous wild type found in 36.2% of subjects): 58% 
strength loss, 50mm soreness (Devaney et al., 2007). 
4) IGF2AS G11711T (homozygous wild type found in 27.8% of subjects): 56% 
strength loss, 56mm soreness, increase in blood CK (17,160 U/l) and Mb (659 
ng/ml) (Devaney et al., 2007).  
In addition, ACTN3 R577X was selected for genotyping due to its potential for 
demonstrating improved endurance performance in homozygous rare allele 
subjects (Yang et al., 2003; Niemi and Majammaa, 2005; Lucia et al., 2006; and 
Eynon et al., 2009). 
Genotyping was performed using Applied Biosystem‟s Taqman allele 
discrimination assay using standard thermal cycling conditions, with genotypes called by 
the 7900HT Real-Time PCR System (Applied Biosystems, CA).  For all the SNPs, the 
Applied Biosystem assay ID is located in Table 3.1 or if the SNP was not available on 

























































Recovery beverages were consumed immediately following the glycogen 
depleting exercise, 2 hours post glycogen depleting exercise, and immediately following 
the subsequent exercise performance trial. The study protocols were performed by each 
subject on three separate occasions (separated by 7-14 days each). Subjects consumed a 
different beverage for each trial. The beverages were provided in a randomly-
counterbalanced, double-blinded design. Beverages were refrigerated at 5
 o
C from 2 
hours prior to each trial until immediately prior to being consumed. Subjects were 
informed that the beverages consisted of the same amount of fluid with different nutrient 





As this genotype study was conducted as part of a larger recovery beverage study, 
it adopted identical protocols that involved the administration of three different 
treatments. However, for the purposes of the current genotype study, only data collected 
from the carbohydrate-only treatment (CHO) and the high-carbohydrate low-protein 
treatment (HCLP) were analyzed. 
 
Carbohydrate-only Beverage (CHO)  
 
The CHO beverage contained 300 kcal, and 75g of carbohydrate, per 625 ml 
serving (12% by volume). To provide an isocaloric and isovolumetric (750 ml) 
comparison to the other beverage, the CHO beverage was consumed along with 
125 ml of water. 
 
High-Carbohydrate, Low-Protein Beverage (HCLP) 
 
Each 250 ml serving of the HCLP beverage contained 300 kcal, 50g carbohydrate, 
25g protein, and 0.5g of fat. To provide an isocaloric and isovolumetric (750 ml) 
comparison to the other beverage, the HCLP mixture was consumed along with 
500 ml of water. 
 
Dietary and Exercise Controls   
 
Subjects were asked not to perform any heavy exercise 48 hours prior to each trial. A 48-
hour diet and exercise log was completed by each subject preceding each treatment trial, 
and participants were instructed to maintain a consistent dietary and exercise habit 
between trials.  No less than 12 hours prior to the start of the exercise, subjects consumed 





subjects followed the standardized dietary protocol consisting of the following 
procedures: 
1) No food or beverage intake between dinner and bedtime on the evening prior to the 
trial (water was consumed ad libitum). 
2) On the morning of the exercise trials, subjects consumed a standardized breakfast two 
hours prior to the glycogen-depleting exercise trial. The meal was provided by the 
researchers, and consisted of 495-510 kcal, including 90-98g carbohydrate, 8-12g protein 
and 4.5-7.5g fat. In order to account for personal tastes, subjects chose from one of 4 
meal choices, but the identical meal chosen was repeated across the four trials for each 
subject. These dietary restrictions ensured that no differences in nutrient intake occurred 
between the intervention periods, other than the treatments provided by the researchers.   
3) No nutrients were consumed between the glycogen depleting trial and the subsequent 
exercise performance trial, other than the recovery beverages provided by the researchers. 
4) No nutrients were consumed for 2 hours following the subsequent exercise 
performance trial, other than the recovery beverages provided by the researchers. 
5) Subjects resumed their normal diets from 2 hours following the subsequent exercise 
performance trial through the 24HrPost measurement period. However, subjects recorded 
their dietary intake during this period, and were instructed to maintain similar dietary 
habits between the different trials. 
 
Statistical Analyses 
SPSS Version 17.0 was used to conduct statistical analyses.  One-way Analysis of 
Variance (ANOVA) was used to analyze main effects for allele groups for time to 





analysis was repeated for each of the five selected genotypes. Pairwise comparisons were 
performed to analyze specific differences in performance variables between allele groups 
for each genotype. To analyze genotype effects on markers of muscle recovery (serum 
CK levels, peak MVC, mental and physical energy/fatigue and muscle soreness ratings), 
repeated measures ANOVAs (RMANOVA) were conducted with „time‟ as the within-
subject factor (pre, post) and „allele group‟ as the between-group factor. Post-hoc 
analyses were conducted using pairwise comparisons to analyze specific differences in 
change scores for each recovery variable between allele groups for each genotype. For 
specific allele groups identified as susceptible to impaired muscle recovery, 
RMANOVAs were conducted within the genotype group, with treatment (CHO, HCLP) 
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Purpose: This study examined the influence of genotype polymorphisms (specifically 
ACTN3 R577X, IGF-II C13790C, IGF-II G17200A, IGF2AS A1364C, IGF2AS 
G11711T) on markers of skeletal muscle recovery following an acute bout of heavy 
endurance exercise, and assessed their role in determining individual responses to 
carbohydrate-protein supplementation. Methods: Twelve trained male cyclists completed 
repeated cycling trials, each consisting of an initial session of glycogen-depleting 
exercise, followed four hours later by a >1 hr time-trial on a computerized cycle 
ergometer (VeloTron, Racermate, Inc). Subjects were randomly administered a high-
carbohydrate low-protein (HCLP), or carbohydrate-only (CHO) beverage, which was 
consumed immediately and 2-hours post glycogen depleting exercise, and immediately 
following subsequent exercise. Beverages were isocaloric and isovolumetric.
 
Blood 
samples were obtained before the glycogen-depleting exercise of the first trial for 
genotyping analysis. Serum creatine kinase (CK), peak muscle function (MVC), mental 
and physical energy and fatigue ratings, and muscle soreness ratings were obtained as 
markers of muscle recovery at specific time points. Subjects completed these methods for 
both treatments in a double-blind protocol. Results: Changes in MVC were significantly 
different (P < 0.05) from baseline to 4-hours post glycogen depleting exercise among 
genotypes for the ACTN3 R577X, IGF-II C13790C, and IGF2AS A1364C single 
nucleotide polymorphisms (SNPs) during the CHO control trial. Changes in 
mental/physical energy/fatigue and muscle soreness ratings were significantly different 
(P < 0.05) from baseline to 24-hours post glycogen depleting exercise among genotypes 





variables tended to improve with the HCLP treatment when subjects identified for the 
above genotype variations were analyzed, although the improvements were not 
statistically significant. Changes in serum CK were not significantly different (P > 0.05) 
from baseline to 4-hours post glycogen depleting exercise among genotypes analyzed. 
Conclusions: Genotype variations led to significant differences in MVC, physical/mental 
energy/fatigue and muscle soreness ratings, which tended to improve with the HCLP 
treatment. There were no genotype effects for serum CK. 





































Prolonged high-intensity endurance exercise is associated with depleted glycogen 
stores and impairments in markers of muscle recovery. Traditionally, sports beverages 
containing water, carbohydrate, and electrolytes have been utilized by endurance athletes 
to enhance glycogen replenishment, facilitate muscle recovery, and improve aerobic 
performance (Hargreaves et al., 1984; Coyle and Coggan, 1984; Coggan and Coyle 1991; 
Coyle, 1992; 1992; Halson, 2004). Recently, the inclusion of protein into carbohydrate-
based sport beverages to confer additional performance benefits has garnered 
considerable attention in the field of exercise science. The inclusion of protein content is 
proposed to enhance the rate of muscle recovery, as well as improve subsequent 
endurance performance (Saunders et al., 2004; Betts et al., 2007; Berardi et al., 2008; 
Rowland et al., 2008; and Skillen et al., 2008). 
Current studies examining the efficacy of carbohydrate-protein supplementations 
have demonstrated mixed results. Some studies have documented improved performance 
in subsequent exercise bouts (Saunders et al., 2004; Betts et al., 2007; Berardi et al., 
2008; Rowland et al., 2008; and Skillen et al., 2008), as well as reductions in markers of 
muscle damage and soreness (Saunders et al., 2004; Millard-Stafford et al., 2005; 
Romano-Ely et al., 2006; Rowland et al., 2008; and Skillen et al., 2008) with 
carbohydrate-protein ingestion. However, other studies have reported no differences in 
subsequent exercise performance between carbohydrate and carbohydrate-protein 
beverages (Millard-Stafford et al., 2005; Romano-Ely et al., 2006; Betts et al., 2007). In 
addition to the variations between studies, there appears to be considerable variations 





ingestion. For example, Combest et al. (2005) reported that 10 of 14 cyclists performing 
exhaustive exercise observed sizable attenuations in post-exercise serum CK levels (ΔCK 
= 975 ± 590 U/L) with carbohydrate-protein ingestion, while the remaining four subjects 
were non-responders (ΔCK = -10.0 ± 31.6 U/L) to carbohydrate-protein intake. 
Furthermore, the carbohydrate-protein „responders‟ experienced improvements in 
subsequent exercise performance that were significantly greater than those who were 
„non-responders‟. 
The variations in findings within current literature suggest that some individuals 
are better responders to carbohydrate-protein supplementation than others, although the 
mechanism for the variations remains unclear. One possible explanation may lie in the 
role of specific genetic polymorphisms. Certain genotypes may predispose individuals to 
greater muscle damage following exercise. Hence, such individuals would potentially 
respond better to sports recovery beverages containing protein. 
Current studies examining genotype associations with muscle damage have 
identified specific genotypes associated with increased skeletal muscle damage following 
acute exercise: MLCK C37885A (Clarkson et al., 2005), IGF-II C13790G, IGF-II 
G17200A, IGF2AS A1364C, IGF2AS G11711T (Devaney et al., 2007), and ACE ID 
(Yamin et al., 2007). However, these studies have primarily incorporated eccentric 
resistance exercise protocols. The association between genotypes and aerobic exercise-
induced muscle damage is therefore not well understood. Hence, the present study seeks 
to determine if genetic polymorphisms (specifically IGF-II C13790G, IGF-II G17200A, 
IGF2AS A1364C, IGF2AS G11711T, and ACTN3 R577X) influence muscle 





susceptibility to cycling induced muscle damage could account for the varied responses 
to recovery beverage supplementation. The findings may help to determine the likelihood 
of individuals responding to recovery beverages containing protein. We hypothesize that 
1) variations in genotypes among subjects will lead to significant differences in serum 
CK levels, peak muscle function, perceived physical/mental energy/fatigue, and 
perceived muscle soreness after acute intense aerobic exercise, and 2) subjects with 
genotypes associated with greater increases in the above muscle damage variables will 
derive greater reductions in these variables, and significant improvements in time to 
completion during a subsequent endurance performance exercise with the ingestion of 





















 Fourteen endurance-trained male cyclists (18-45 yrs) were recruited from James 
Madison University and the surrounding area. The inclusion criteria included a minimum 
of three days a week of cycling for the past 2 months, and a peak aerobic capacity 
(VO2peak) greater than 45 ml/kg/min. All subjects received a written consent form that 
described the risks and benefits associated with the study. After a description of the 
protocols, subjects signed the written consent form. James Madison University 
Institutional Review Board approved the experiment design before data collection began. 
Procedures 
 
The study design consisted of a pre-testing/screening phase, familiarization trial, 
and three treatment trials.   
Pre-testing Phase  
 All potential subjects that met the study criteria completed the following 
assessments.   
Body Mass and Height  
Subjects had their body weight measured to the nearest 0.1kg and height 
measured to the nearest 0.5cm. 
VO2peak/Wmax  
Subjects completed an exercise test to determine their peak oxygen uptake 
(VO2peak) and associated power output (Wmax). The test began with subjects riding 
a cycle ergometer at a self-selected pace, described as a “comfortable but not easy 





output was increased by 25 W every 2 minutes until the subject voluntary 
requested to stop the test due to fatigue. Peak oxygen uptake and power output 
were measured during the test to determine if subjects met entry criteria for the 
study, and to establish intensities for subsequent exercise protocols.   
Familiarization Trial 
All subjects that met the inclusion criteria performed a familiarization trial within 
two weeks of the pre-testing assessment. The purpose of the familiarization trial was to 
determine if the exercise intensities were appropriate for each subject. The familiarization 
trial also allowed subjects to become acclimated to the protocol and establish the 
appropriate pace for the time-trial segment. Subjects were tested prior to the treatment 
phase in order to alter workloads and to ensure they can complete the treatment trial. 
Another purpose of the familiarization trial was to minimize any effects of learning and 
the repeated-bout effect, in order to reduce error variance between treatment trials. All 
subjects received the CHO recovery beverage during the familiarization trial (described 
below). The treatment phases began 7 to 10 days following the familiarization trial. No 
blood draws or muscle recovery measures were taken during the familiarization trial. 
Treatment Phases  
Treatment phases were similar to the familiarization trial with the addition of the 
supplementation treatment provided during the trial, and the inclusion of blood draws and 
muscle recovery measures. The treatment phase consisted of a glycogen-depleting 
exercise, a recovery period and a subsequent time trial.  
A visual timeline of events during each of the treatment phase is provided in 





Figure 4.1: Timeline for exercise trials and measurements of recovery. 
 
PRE:              Post:   0.5HrPost:   2HrPost:  4HrPost:    Post:   24HrPost: 
MS MVC   IN         TB         MS MVC MS 
MPEF TB   GL          MPEF TB MPEF 
CK               MVC       CK 
MVC      MVC  
           4 hours 
      
                                                                                    
         24 hours 
 
MS=Muscle Soreness, MPEF= Mental/Physical Energy/Fatigue, CK=Creatine Kinase,  
MVC= Peak Isometric Torque, TB=Treatment Beverage, IN=Insulin, GL=Gluose 
 
Glycogen-depleting exercise  
Subjects performed a steady state warm-up for 10 minute at 60% Wmax. 
After the initial 10 minutes of exercise, subjects completed a series of 2 minute 
high-intensity intervals. The high-intensity intervals consisted of 2 minutes at 
95% Wmax at a cadence of 70 rpm, followed by 2 minutes at 50% Wmax. Once the 
cadence dropped below 70 rpm, the workloads for the high-intensity intervals 
were decreased to 85% Wmax, with the cadence remaining at 70 rpm. Once the 
cadence dropped below 70 rpm again, the workload for the high-intensity 
intervals was further decreased to 75% Wmax. The test was terminated when 
subjects failed to maintain a cadence of 70 rpm at this intensity. This protocol was 
designed to induce muscle glycogen depletion and moderate fatigue (Kuipers et 
al., 1987). Based on similar findings from Karp et al (2006) and Van Loon et al 
(2000), the duration of the test was expected to last approximately 50-75 minutes, 
with 30-45 minutes of high-intensity intervals. All subjects were permitted to 













Recovery Period  
Following the glycogen-depleting exercise there was a 4 hour period of 
recovery. Subjects consumed 750 ml of a recovery beverage immediately 
following this trial and again 2-hours post-exercise (see „treatment beverage‟ 
below for description).  
Subsequent Exercise Performance 
After the 4 hour recovery period, subjects performed an endurance 
performance trial on a computerized cycle ergometer (VeloTron, Racermate, Inc). 
The start of the trial consisted of 20 minutes at a steady-state pace, with intensity 
corresponding to 60% Wmax. The purpose of the steady state segment was to 
assess steady-state substrate utilization, and to ensure depletion of muscle 
glycogen. Following 20 minutes of steady-state exercise, subjects completed a 
simulated 20 km time trial. The last 5 km of the course consisted an uphill 
segment at 5% elevation. This was included in the protocol to allow an 
assessment of late-exercise performance. 
 All trials were performed at ambient room temperature (70-72
 o
F). The 
subjects were asked to void their bladders prior to all trials. A Windmere fan, set 
on „medium‟ speed, was placed 2 meters from the handlebars of the ergometer for 
cooling purposes during the trial. Water was provided ad libitum throughout all 
trials. Each subject was asked to provide maximal effort and treat each time trial 
as a competitive event. For consistency, no verbal encouragement was provided to 
the subjects during the time trial. The only feedback subjects received during the 





 Subjects were given at least one week between trials to ensure complete 
recovery. Participants were allotted 14 days to complete a trial in the event of 
unrelated illness or unforeseen circumstances, which occurred in four subjects. 
Dependent measurements 
Subsequent Exercise Performance 
 
 Exercise performance was measured using cycling time to completion for the 20 
km time trial. Time was also recorded during the final 5km of the course.  
Physiological Responses during Steady-State Exercise 
Metabolic Measurements 
 
Metabolic measurements were obtained during the glycogen-depleting 
trial and during the steady-state segment of the subsequent performance trial 
using a SensorMedics Spectra metabolic cart. These measurements were obtained 
after 3 minutes of cycling during the glycogen depleting trial (at 60% Wmax) and 
after 3 minutes of cycling during the subsequent performance trial (also at 60% 
Wmax). Expired respiratory gases were collected for 5 minutes at each time point. 
Average values were calculated using the final 3 minutes of each time period, 
following 2 minutes of breathing equilibration. Measurements obtained from the 
expired gases included oxygen uptake (VO2), ventilation (VE), and respiratory 
exchange ratio (RER).  
Blood Glucose and Lactic Acid 
 
Blood samples were obtained immediately prior to exercise, during the 
glycogen-depleting trial (at minute 8) and exercise performance trial (at minute 





during each point via a finger-stick. An automated analyzer (YSI 2300 STAT 
glucose/lactate analyzer) determined glucose and lactate levels.  
Serum Insulin 
 
Thirty minutes after consuming the recovery beverage, 5 ml of blood was 
collected using a venous blood draw from an antecubital vein. The blood was 
collected in SST clot agent Vacutainer
®
 tubes, centrifuged, and serum stored at -
80
 o
C. Insulin levels were assessed from the serum through a commercially-
available ELISA assay (ALPCO Diagnostics, Salam, NH). 
Heart Rate 
 
Heart rate was recorded using a Polar heart rate monitor (Lake Success, 
NY). Measurements were obtained at minute 8 of the glycogen-depleting trial and 
the subsequent exercise trial. Average heart was also recorded for the 20 km time 
trial and the final 5 km segment.   
Ratings of Perceived Exertion (RPE) 
 
Ratings of perceived exertion were obtained by having the subjects point 
to a corresponding level of exertion on the Borg RPE scale (6-20). The RPE 
recording was collected at the 8 minute mark during the glycogen-depleting and 
subsequent exercise. The following statement was read to the subjects to explain 
the RPE scale: “Please describe your current level of exertion using the following 
scale. This level should represent your overall perception of effort, and not 
localized to a specific group of muscles, etc. For reference, a 6 would represent 
your effort when you are resting or watching TV, while 20 would represent the 





Muscle Recovery Variables 
 
Muscle recovery variables included ratings of muscle soreness, mental and 
physical energy/fatigue ratings, isometric peak torque (MVC), and serum creatine kinase 
(CK). Muscle soreness ratings and mental/physical energy/fatigue ratings were collected 
during the following three time points; prior to the glycogen depletion trial (PRE), prior 
to the subsequent exercise performance trial (4HrPost) and 24 hours following the 
glycogen depletion trial (24HrPost). Serum CK was obtained twice: PRE and 24HrPost. 
Peak MVC was assessed five times: PRE, 4HrPost, 24HrPost, as well as immediately 
after the glycogen depleting trial and subsequent trial. A visual timeline of the muscle 
recovery measurements is provided in Figure 4.1 above. 
Serum Creatine Kinase (CK) 
 Serum CK was measured as an indirect indicator of muscle damage. 
Approximately 5ml of blood were obtained using a venous blood draw from an 
antecubital vein prior to exercise and 24-hr post exercise. Using a centrifuge, 
whole blood was spun at 7000 rpm to separate serum and stored in a -80
 o
 C 
freezer. Serum CK was analyzed using a Johnson and Johnson Vitro DT6011. The 
measurement device was calibrated prior to analyses using a reconstituted 
lyophilized calibration standard purchased from the manufacturer. 
Muscle Function Test/Isometric peak torque (MVC) 
 
 Peak torque of the knee extensors were assessed to determine treatment 
differences in muscle function during recovery from exercise. Subjects were 
seated in a modified leg extension chair and asked to push as hard as possible 





performed 3 to 6, 5-second repetitions at each time-point. There was a 1 minute 
rest between each repetition. MVC was also assessed immediately following both 
exercise sessions. 
Mental and Physical Energy/Fatigue Ratings 
 
 The Mental and Physical State and Trait Energy and Fatigue Scales 
(MPSTEFS, O‟Conner, 2004) were used to record ratings of mental and physical 
energy. Separate ratings of physical energy, physical fatigue, mental energy and 
mental fatigue were obtained using visual analog scales, with potential scores 
ranging from 0 to 300 for each rating.  
Muscle Soreness Ratings 
 
During the familiarization trial subjects received instruction on how to 
utilize the muscle soreness scale. The following statement was read to the 
subjects; “please describe your overall level of muscle soreness that you feel 
currently while performing normal daily activities (i.e. walking up or down 
stairs)”. The soreness rating used a 100mm visual analog scale; 0 indicated no 
muscle soreness and 100 indicated impaired movement due to muscle soreness.  
Genotypes 
 Single nucleotide polymorphisms (SNPs) were evaluated in this study to 
determine if specific variations in these polymorphisms were associated with variations 
in muscle recovery variables, and examine their influence on individual responses to 
recovery beverages with protein. The following SNPs were evaluated in this study: 
ACTN3 R577X, IGF-II C13790G, IGF-II G17200A, IGF2AS A1364C, and IGF2AS 





an antecubital vein prior to the glycogen depleting exercise during the first trial, and 
mixed through inversion. DNA was isolated from each blood sample using the QIAamp® 
DNA Blood Mini Kit (Qiagen, CA). Subject identification information was removed for 
all DNA samples, which were subsequently shipped to the Research Center for Genetic 
Medicine at the Children‟s National Medical Center in Washington D.C. for genotyping. 
The following polymorphisms were selected for genotyping based on their susceptibility 
to impaired muscle recovery as demonstrated by increased serum CK levels, strength 
loss, and muscle soreness following eccentric resistance exercises in prior research: 
1) IGF-II C13790G (homozygous rare allele found in 18.6% of subjects): 58% 
strength loss immediately post-exercise, increased serum CK activity at 7 days 
post-exercise (8818 U/l) (Devaney et al., 2007).  
2) IGF-II G17200A (homozygous rare allele found in 11.0% of subjects): 60% 
strength loss immediately post-exercise, increased CK activity at 7 days post-
exercise (12261 U/l) (Devaney et al., 2007). 
3) IGF2AS A1364C (homozygous wild type found in 36.2% of subjects): 58% 
strength loss, 50mm soreness (Devaney et al., 2007). 
4) IGF2AS G11711T (homozygous wild type found in 27.8% of subjects): 56% 
strength loss, 56mm soreness, increase in blood CK (17,160 U/l) and Mb (659 
ng/ml) (Devaney et al., 2007).  
In addition, ACTN3 R577X was selected for genotyping due to its potential for 
demonstrating improved endurance performance in homozygous rare allele 
subjects (Yang et al., 2003; Niemi and Majammaa, 2005; Lucia et al., 2006; and 





Genotyping was performed using Applied Biosystem‟s Taqman allele 
discrimination assay using standard thermal cycling conditions, with genotypes called by 
the 7900HT Real-Time PCR System (Applied Biosystems, CA).  For all the SNPs, the 
Applied Biosystem assay ID is located in Table 4.1 or if the SNP was not available on 
the ABI website than a custom primer set was designed. 













































Recovery beverages were consumed immediately following the glycogen 
depleting exercise, 2 hours post glycogen depleting exercise, and immediately following 
the subsequent exercise performance trial. The study protocols were performed by each 
subject on three separate occasions (separated by 7-14 days each). Subjects consumed a 
different beverage for each trial. The beverages were provided in a randomly-
counterbalanced, double-blinded design. Beverages were refrigerated at 5
 o





hours prior to each trial until immediately prior to being consumed. Subjects were 
informed that the beverages consisted of the same amount of fluid with different nutrient 
composition, but were not informed the specific composition of the different beverages.  
As this genotype study was conducted as part of a larger recovery beverage study, 
it adopted identical protocols that involved the administration of three different 
treatments. However, for the purposes of the current genotype study, only data collected 
from the carbohydrate-only treatment (CHO) and the high-carbohydrate low-protein 
treatment (HCLP) were analyzed. 
Carbohydrate-only Beverage (CHO)  
 
The CHO beverage contained 300 kcal, and 75g of carbohydrate, per 625 
ml serving (12% by volume). To provide an isocaloric and isovolumetric (750 ml) 
comparison to the other beverage, the CHO beverage was consumed along with 
125 ml of water. 
High-Carbohydrate, Low-Protein Beverage (HCLP)  
 
Each 250 ml serving of the HCLP beverage contained 300 kcal, 50g 
carbohydrate, 25g protein, and 0.5g of fat. To provide an isocaloric and 
isovolumetric (750 ml) comparison to the other beverage, the HCLP mixture was 
consumed along with 500 ml of water. 
Dietary and Exercise Controls   
 
Subjects were asked not to perform any heavy exercise 48 hours prior to each 
trial. A 48-hour diet and exercise log was completed by each subject preceding each 
treatment trial, and participants were instructed to maintain a consistent dietary and 





subjects consumed their final self-selected meal (dinner the evening prior to testing). 
After this meal, subjects followed the standardized dietary protocol consisting of the 
following procedures: 
1) No food or beverage intake between dinner and bedtime on the evening prior to the 
trial (water was consumed ad libitum). 
2) On the morning of the exercise trials, subjects consumed a standardized breakfast two 
hours prior to the glycogen-depleting exercise trial. The meal was provided by the 
researchers, and consisted of 495-510 kcal, including 90-98g carbohydrate, 8-12g protein 
and 4.5-7.5g fat. In order to account for personal tastes, subjects chose from one of 4 
meal choices, but the identical meal chosen was repeated across the four trials for each 
subject. These dietary restrictions ensured that no differences in nutrient intake occurred 
between the intervention periods, other than the treatments provided by the researchers.   
3) No nutrients were consumed between the glycogen depleting trial and the subsequent 
exercise performance trial, other than the recovery beverages provided by the researchers. 
4) No nutrients were consumed for 2 hours following the subsequent exercise 
performance trial, other than the recovery beverages provided by the researchers. 
5) Subjects resumed their normal diets from 2 hours following the subsequent exercise 
performance trial through the 24HrPost measurement period. However, subjects recorded 
their dietary intake during this period, and were instructed to maintain similar dietary 
habits between the different trials. 
Statistical Analyses 
SPSS Version 17.0 was used to conduct statistical analyses.  One-way Analysis of 





completion for the 20 km and final 5 km during subsequent exercise performance. This 
analysis was repeated for each of the five selected genotypes. Pairwise comparisons were 
performed to analyze specific differences in performance variables between allele groups 
for each genotype. To analyze genotype effects on markers of muscle recovery (serum 
CK levels, peak MVC, mental and physical energy/fatigue and muscle soreness ratings), 
repeated measures ANOVAs (RMANOVA) were conducted with „time‟ as the within-
subject factor (pre, post) and „allele group‟ as the between-group factor. Post-hoc 
analyses were conducted using pairwise comparisons to analyze specific differences in 
change scores for each recovery variable between allele groups for each genotype. For 
specific allele groups identified as susceptible to impaired muscle recovery, 
RMANOVAs were conducted within the genotype group, with treatment (CHO, HCLP) 


















The sample population demographics (age, height, body mass, peak aerobic 
capacity, and power output) of the 12 trained male cyclists from which viable DNA could 







 percentile for maximal aerobic power based on age-specific norms 
prescribed by ACSM (2010). 
Table 4.2: Subject Demographics. 
Variable Mean ± SEM 
Age (y) 25.5 ± 2.3 
Height (cm) 177.5 ± 2.2 







65.5 ± 2.1 
351.7 ± 9.8 
 
Genotypes 
The genotype distributions of the sample population are presented in Table 4.3. 
They include genotype and allele frequencies for ACTN3 SNPs, IGF-II SNPs, and 
IGF2AS SNPs. All 12 subjects were homozygous for the wild-type allele of IGF-II ApaI 
(G17200A). Hence, analyses of genotype variations on subsequent performance and 
markers of recovery were not performed for the IGF-II ApaI G17200A SNP.  




   SNP/(rs number)  
  Homozygous  
    Wild Type 
 
Heterozygous 




ACTN3 R577X (rs1815739) 2 (16.7%, RR) 8 (66.7%, RX) 2 (16.7%, XX)    0.500/0.500 
IGF-II C13790G (rs3213221) 6 (50%, CC) 6 (50%, CG) 0 (0%, GG)    0.750/0.250 





2 (16.7%, AA) 
2 (16.7%, GG) 
5 (41.7%, AC) 
7 (58.3%, GT) 
5 (41.7%, CC) 
3 (25.0% TT) 
   0.375/0.625 











Performance variables for the subsequent exercise trial (time for 20 km and final 
5 km) are presented in Table 4.4. The CHO treatment served as the „control‟ trial. Thus, 
all analyses of the influence of genotype on exercise/performance were performed using 
data from the CHO trial. 
Table 4.4: Subsequent Exercise Performance  
– 20 km Time Trial (CHO Treatment). 
Variable Mean ± SEM 
Total time to completion 48.5 + 1.5 
for 20 km (min) 
 




19.6 + 0.9 
 
 
Genotype effects on subsequent performance were examined for the CHO 
treatment, and the findings are presented in Table 4.5. Subjects homozygous for the wild-
type allele of IGF2AS G11711T demonstrated significantly slower time to completion for 
the 20 km time trial (P < 0.05), as well as significantly slower time for the final 5 km 
climb (P < 0.05). Subjects homozygous for the rare allele of ACTN3 R577X exhibited a 
potential trend towards faster ride times in the final 5 km climb (P < 0.10). However, the 
difference was not statistically significant (P > 0.05). No significant genotype effects 
were observed for any other genotypes on subsequent exercise performance.  








Mean ± SEM 















Heterozygous Wild Type (GT, n = 7)  
Homozygous Rare Allele (TT, n = 3) 
 
Homozygous Wild Type (AA, n = 2) 
Heterozygous Wild Type (AC, n = 5) 
Homozygous Rare-Allele (CC, n = 5) 
 
47.3 + 1.9 
46.5 +1.2 
 
45.5 + 1.0 
49.3 + 1.9 





































Homozygous Wild Type (CC, n = 6) 
Heterozygous Wild Type (CG, n = 6) 
 
Homozygous Wild Type (RR, n = 2) 
Heterozygous Wild Type (RX, n = 8) 
Homozygous Rare Allele (XX, n = 2)
 
 
Homozygous Wild Type (GG, n = 2)** 
Heterozygous Wild Type (GT, n = 7)  
Homozygous Rare Allele (TT, n = 3) 
 
Homozygous Wild Type (AA, n = 2) 
Heterozygous Wild Type (AC, n = 5) 
Homozygous Rare Allele (CC, n = 5) 
 
Homozygous Wild Type (CC, n = 6) 
Heterozygous Wild Type (GC, n = 6) 
 
Homozygous Wild Type (RR, n = 2) 
Heterozygous Wild Type (RX, n = 8) 
Homozygous Rare Allele (XX, n = 2)
^
 
47.8 + 1.5 
49.2 + 2.7 
 
50.9 + 6.0 
49.2 + 1.5 
43.3 + 3.3 
 
24.5 + 1.4 
18.7 + 1.1 
18.7 + 0.7 
 
18.1 + 0.7 
19.8 + 1.0 
20.1 + 2.1 
 
19.5 + 0.8 
19.8 + 1.7 
 
22.1 + 3.8 
19.9 + 0.8 
16.4 + 3.4 
* signifies a trend towards a difference (P < 0.10) 
#
 significantly different from each other (P < 0.05) 
** GG times were significantly slower (P < 0.05) than GT and TT 
^ signifies a trend towards faster times for XX than RR (P < 0.10) 
 
 Based on the above findings in the CHO control trial, the genotypes that were 
most likely to be associated with differences in subsequent performance were compared 
against the HCLP trial to determine if possible treatment effects between CHO and 
HCLP were influenced by genotypes. There were no significant treatment x genotype 
interactions for 20 km and final 5 km times (Table 4.6).  
Table 4.6: Treatment by Genotype interaction in Subsequent Exercise. 
Variable Genotype/SNP/(rs) Treatment  P Value (treatment x genotype interaction) 
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   0.258 
 
 
   0.941 
 
 






The markers of muscle recovery following the glycogen depleting exercise were 
examined for the CHO treatment, and findings are presented in Table 4.7. There was a 
small but significant increase in CK from pre-exercise to 24-hours post exercise (25.0 
U/L, P < 0.05). Peak muscle function (MVC) trended towards higher levels 24-hours 
post-exercise (P < 0.10), and tended to be lower immediately following glycogen 
depleting exercise, but these tendencies were not statistically significant (P > 0.05). There 
were significant declines (P < 0.05) in physical energy and mental energy ratings, and 
significant increases (P < 0.05) in physical fatigue and mental fatigue ratings from pre-
exercise to 4-hours post exercise. No significant differences were observed in any of the 
above ratings from pre-exercise to 24-hours post exercise. Muscle soreness ratings were 
significantly elevated (P < 0.05) from pre-exercise to 4-hours post exercise, and from pre-
exercise to 24-hours post exercise. 
Table 4.7: Markers of Recovery for CHO Treatment. 
Variables Time Point Mean ± SEM 

































161.1 + 17.0* 
 
 
451.1 + 29.9 
427.2 + 41.2 
445.9 + 24.8 
489.5 + 34.7* 
 
10.5 + 3.2 
36.0 + 5.2* 
24.9 + 6.5* 
 
200.3 + 18.2 
159.7 + 17.5** 




























79.2 + 16.9 
148.1 + 19.0* 
87.5 + 17.6 
 
194.7 + 20.3 
174.6 + 17.8** 
200.6 + 19.2 
 
94.4 + 19.4 
117.5 + 17.6* 
89.3 + 20.1 
PreGE = pre glycogen depleting exercise, 0Post = 0 hours post glycogen depleting 
exercise, 4Post = 4 hours post glycogen depleting exercise, 24Post = 24 hours post 
glycogen depleting exercise. 
* significant increase from PreGE (P < 0.05) 
** significant decline from PreGE (P < 0.05) 
 
The change scores of muscle damage/recovery variables for the CHO treatment 
(control trial) were analyzed for genotype effects, and significant findings are presented 
in Table 4.8.  
Subjects homozygous for the wild-type allele of ACTN3 R577X demonstrated 
significantly greater losses in peak MVC from pre to 4-hours post exercise than 
heterozygous subjects (P < 0.05). The loss of peak muscle function in the wild-type allele 
group also tended to be larger, (but not significantly so) when compared to subjects 
homozygous for the rare allele of ACTN3 R577X (P > 0.05). Subjects homozygous for 
the rare allele of IGF2AS A1364C demonstrated significantly greater declines in peak 
MVC from pre to 4-hours post exercise compared to subjects homozygous for the wild 
allele (P < 0.05). When genotyped for IGF-II C13790G, heterozygous subjects 
demonstrated significantly greater declines in peak MVC than subjects homozygous for 
the wild-type allele (P < 0.05). There were no genotype effects observed for changes in 





When genotyped for the IGF2AS G11711T SNP, significant differences (P < 
0.05) were observed between genotypes for changes in physical fatigue ratings from pre-
exercise to 4-hours and 24-hours post exercise, and for changes in mental fatigue ratings 
from pre-exercise to 24-hours post exercise (see Table 4.8). When genotyped for ACTN3 
R577X, changes in physical energy ratings were significantly different between 
genotypes from pre-exercise to 4-hours post-exercise (P < 0.05), and a trend towards 
significance from pre-exercise to 24-hours post exercise (P < 0.10). There were no 
genotype effects observed for changes in physical/mental energy/fatigue ratings at any 
time point when subjects were genotyped for IGF-II C13790G and IGF2AS A1364C.  
Changes in muscle soreness ratings demonstrated a trend towards significance 
from pre-exercise to 24-hours post exercise when genotyped for IGF 2AS G11711T. 
There were no significant genotype effects observed for changes in serum CK responses.  










 + SE 
ACTN3 R577X 
(rs1815739) 
   Peak Muscle Function 
 
 
   
   Physical Energy ratings 
 
 
    
   Physical Energy ratings 
 
 
    























































RR (n = 2, 66.3 + 40.4)* 
RX (n = 8, -11.9 +10.4)* 
XX (n = 2, 12.5 + 38.7) 
 
RR (n = 2, 78.8 + 15.8) 
RX (n = 8, 20.6 +10.0)** 
XX (n = 2, 82.5 + 18.5) 
 
RR (n = 2, 40.5 + 35.0)*
#
 
RX (n = 8, -8.4 + 7.7)* 
XX (n = 2, -7.8 + 5.3)
# 
 
RR (n = 2, 33.8 + 70.8)* 
RX (n = 8, -9.8 + 13.0)* 




CC (n = 6, -23.5 + 11.6)* 













   Physical Energy ratings 
 
 
    
   Mental Energy ratings 
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PreGE – 24Post 
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AA (n = 2, -49.7 + 23.6)* 
AC (n = 5, 1.6 + 7.8) 





GG (n = 2, 33.0 + 42.5)
#
 
GT (n = 7, -11.8 + 8.2)
#
 
TT (n = 3, 5.0 + 5.0)
 
 
GG (n = 2, 12.8 + 3.8) 
GT (n = 7, 34.3 + 8.0)* 
TT (n = 3, -8.3 + 22.3)*
 
 
GG (n = 2, 52.0 + 57.5)*
#
 
GT (n = 7, -17.9 + 9.1)* 
TT (n = 3, -16.7 + 18.8)
# 
 
GG (n = 2, 120.5 + 9.0)* 
GT (n = 7, 72.0 + 8.9)
#
 
TT (n = 3, 27.3 + 26.9)*
# 
 
GG (n = 2, 98.3 + 21.3)** 
GT (n = 7, -14.8 + 9.6) 
TT (n = 3, 2.2 + 4.7)
 
GG (n = 2, 36.8 + 18.3) 
GT (n = 7, 32.9 + 11.1)
#
 
TT (n = 3, -9.0 + 21.9)
# 
 
GG (n = 2, 75.3 + 29.3)** 
GT (n = 7, -20.8 + 9.0) 
TT (n = 3, -22.3 + 21.9)
 
 
GG (n = 2, 36.8 + 19.8)
#
 
GT (n = 7, 11.9 + 6.9) 
TT (n = 3, 5.5 + 3.6)
#
 
PreGE = pre glycogen depleting exercise, 4Post = 4 hours post glycogen depleting 
exercise, 24Post = 24 hours post glycogen depleting exercise. 
1
Larger change scores in peak muscle function, physical/mental energy ratings represent 
greater declines in the respective variables, while larger change scores in physical/mental 
fatigue and muscle soreness ratings represent greater increases in those variables. 
* significantly different from each other (P < 0.05) 
** significantly different than the other two groups (P < 0.05) 
# signifies a trend towards a difference (P < 0.10) 
Based on the above findings in the CHO control trial, the genotypes that were 





compared against the HCLP trial to examine whether genotypes influenced potential 
treatment effects on recovery measurements. A summary of these treatment x time x 
genotype analyses are shown in Table 4.9.   
Table 4.9: Treatment x time within Genotypes on markers of muscle recovery. 
Gene/SNP/(rs number)/Variable Time points Treatment P Value (treatment effect) 
ACTN3 R577X 
(rs1815739) 
   Peak Muscle Function 
 
 
   Physical Energy ratings 
 
 
   Physical Energy ratings 
 
    










   Peak Muscle Function 
 
 
PreGE – 4Post  
 
 
PreGE – 4Post 
 
 
PreGE – 24Post 
 
 










PreGE – 4Post  
 
 
   CHO 
   HCLP 
 
   CHO 
   HCLP 
 
   CHO 
   HCLP 
 
   CHO 




   CHO 












  0.960 
 
 
  0.135 
 
 

















   Physical Energy ratings 
 
 
   Mental Energy ratings 
 
 
   Mental Energy ratings 
 
 
   Physical Fatigue ratings 
 
 
   Physical Fatigue ratings 
 
 






PreGE – 24Post 
 
 
PreGE – 4Post  
 
 
PreGE – 24Post 
 
 
PreGE – 4Post 
 
 
PreGE – 24Post 
 
 
PreGE – 4Post 
 




   CHO 
   HCLP 
 
   CHO 
   HCLP 
    
   CHO 
   HCLP 
 
   CHO 
   HCLP 
 
   CHO 
   HCLP 
 
   CHO 





  0.920 
 
 
  0.008* 
 
   
  0.333 
 
 
  0.232 
 
 
  0.136 
 
 






   Mental Fatigue ratings 
 
 
   Muscle Soreness ratings 
 
PreGE – 24Post 
 
 
PreGE – 24Post 
   CHO 
   HCLP 
 
   CHO 
   HCLP 
  0.123 
 
 
  0.031* 
* significantly different from each other (P < 0.05) 
# signifies a trend towards a difference (P < 0.10) 
 Treatment x time analyses were performed within the genotype groups that were 
identified to be susceptible to impaired muscle recovery following heavy endurance 
exercise (Table 4.10). Small sample-sizes (n = 2 – 6) precluded any strong likelihood to 
observe statistically significant differences between treatments. However, visual analysis 
of the means showed that markers of muscle recovery improved with the HCLP treatment 
in nine of the fourteen variables examined (Table 4.10). Three variables were identical 
between treatments and two variables showed worsened scores with the HCLP treatment.  
Table 4.10: Treatment x Time Effects on markers of muscle recovery within 








Mean + SEM 
P Value (treatment  
x time effect) 
ACTN3 R577X 
(rs1815739) 
Homozygous Wild-Type (RR, n = 2) 




    





   Physical Energy ratings 
 
    
 
 








   CHO 
    
   HCLP 
 
    
   CHO 
    
   HCLP 
 
 
   CHO 
    
   HCLP 
 
 
   CHO 
    






    PreGE  
    4Post  
    PreGE  
    4Post 
     
    PreGE 
    4Post 
    PreGE 
    4Post 
 
    PreGE 
    24Post 
    PreGE 
    24Post 
 
    PreGE 
    24Post 
    PreGE 





588.5 + 165.7 
522.2 + 125.3 
565.3 + 119.1 
603.2 + 161.9 
 
180.5 + 84.5 
101.8 + 68.8 
181.0 + 105.0 
105.0 + 27.0 
 
180.5 + 84.5 
140.0 + 49.5 
181.0 + 105.0 
156.8 + 93.3 
 
149.8 + 72.3 
100.3 + 12.3 
171.0 + 68.0 





       0.429* 
 
 
   
 





















Heterozygous Wild-Type (CG, n = 6) 








Homozygous Rare Allele (CC, n = 2) 




   CHO 
    






    




    PreGE 
    4Post  
    PreGE 






     PreGE 




484.4 + 56.2 
450.6 + 43.4 
483.0 + 40.3 






484.6 + 67.6 




















Homozygous Wild-Type (GG, n = 2) 




   
 
   Mental Energy ratings 
 
    
 
 











   Physical Fatigue ratings 
 
 
    
 












   CHO 
    




   CHO 
    
   HCLP 
 
 
   CHO 
    




   CHO 
    
   HCLP 
 
 
   CHO 




   CHO 
    
   HCLP 
 
 
     PreGE 






     PreGE 
     24Post 
     PreGE 
     24Post  
 
 
     PreGE 
     4Post 
     PreGE 
     4Post 
 
     PreGE 
     24Post 
     PreGE 
     24Post 
 
 
     PreGE 
     4Post 
     PreGE 
     4Post 
 
     PreGE 
     24Post 
     PreGE 
     24Post 
 
     PreGE 
     4Post 
     PreGE 
     4Post 
 
522.8 + 51.9 






193.8 + 71.3 
160.8 + 28.8 
214.0 + 72.0 
169.3 + 80.8 
 
 
172.3 + 49.8 
159.5 + 46.0 
186.5 + 52.5 
92.3 + 2.8 
 
172.3 + 49.8 
120.3 + 7.8 
186.5 + 52.5 
179.0 + 82.0 
 
 
52.5 + 31.5 
173.0 + 22.5 
56.0 + 45.0 
175.0 + 23.0 
 
52.5 + 31.5 
150.8 + 10.3 
56 + 45.0 
124.5 + 51.5 
 
94.5 + 2.5 
131.3 + 20.8 
76.5 + 16.5 






















































   Muscle Soreness ratings 
 
   CHO 
    
   HCLP 
 
 
   CHO 
   
   HCLP 
     PreGE 
     24Post 
     PreGE 
     24Post 
 
     PreGE 
     24Post 
     PreGE 
     24Post 
94.5 + 2.5 
169.8 + 26.8 
76.5 + 16.5 
84.8 + 58.8 
 
17.5 + 15.5 
54.3 + 4.3 
14.0 + 11.0 
24.5 + 5.0 





       0.194* 
* improvements observed with HCLP treatment 
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 The genotype distributions and allele frequencies of the ACTN3 R577X, IGF-II 
C13790G, and IGF2AS G11711T SNPs in the sample population are similar to those 
reported by Clarkson et al. (2005) and Devaney et al. (2007).   The population frequency 
of the IGF-II G17200A and IGF2AS A1364C SNPs differed from the findings of 
Devaney et al. In our study, subjects were exclusively homozygous for the wild-type 
allele of IGF-II G17200A, and there were more subjects homozygous for the rare allele 
than the wild-type allele of IGF2AS A1364C. These discrepancies could be attributed to 
a small sample size (n = 12) and possibly an all-Caucasian sample in the present study, 
compared to a larger and more diverse sample population analyzed by Devaney et al (J M 
Devaney, personal communication, April 2, 2010). 
 The most important findings in this study were that the ACTN3 R577X, IGF-II 
C13790C, IGF2AS A1364C, and IGF2AS G11711T SNPs were associated with 
alterations in markers of muscle recovery following heavy endurance exercise. In 
addition, ACTN3 R577X and IGF2AS G11711T SNPs were observed to be potentially 
associated with subsequent aerobic exercise performance. 
 Subjects homozygous for the wild-type allele of IGF2AS G11711T SNP had 
significantly slower times to completion during subsequent exercise for the 20 km (55.8 
+ 1.1 min) and final 5 km (24.5 + 1.4 min) in the CHO control trial than heterozygous or 
homozygous rare allele subjects. This could be attributed to a greater impairment of 
muscle recovery, as demonstrated by a substantial increase in physical fatigue ratings 
(120.5 + 9.0 mm), and an increase in mental fatigue ratings (36.8 + 18.3 mm) from pre to 





with the findings of Devaney et al., who reported impaired muscle function following 
eccentric resistance exercise in homozygous wild-type subjects (2007). Alternatively, this 
genotype could have influenced the general performance capacity of the individual 
subjects, rather than recovery per se. This possibility is supported by the observation that 
homozygous wild-type subjects completed only 42.3 + 7.3 min in their glycogen 
depleting trial, compared to >60 min in the other genotype groups.    
 Subjects homozygous for the rare allele of ACTN3 R577X trended towards faster 
ride times for the final 5 km (16.4 + 3.4 min) in the CHO control trial than heterozygous 
and homozygous wild-type subjects (P < 0.10). Faster ride times were also recorded for 
rare allele subjects during the 20 km ride (43.3 + 3.3 min), but they were not significantly 
different (P > 0.05) than the other allele groups. The expression of ACTN3 has been 
discovered to be limited to a subset of Type II fast twitch muscle fibers (North and 
Beggs, 1996). The 577X polymorphism results in deficiency of the alpha-actinin-3 
protein, and this mutation may manifest more commonly in certain populations. Findings 
from Yang et al. (2003), Niemi and Majammaa (2005), Lucia et al. (2006), and Eynon et 
al. (2009) revealed a higher frequency of the XX (ACTN3 null) rare allele in endurance 
athletes (distance runners and elite cyclists), compared to a higher frequency of the RR 
allele in elite sprinters. In addition, Vincent et al. observed significantly greater 
distributions of Type IIx fibers in RR than XX-allele subjects (2007). These findings 
suggest that the R allele may be more associated with anaerobic sprint performance, 
whereas the X allele may be more associated with endurance performance. Hence, while 
the time to completion may not be significantly different in our study, the results agreed 





supports our previous statement that the genotype may be influencing general 
performance capacity more than „recovery‟. 
There were no significant changes in CK responses from pre-exercise to 24-hours 
post exercise during the CHO control trial in all genotype groups. A possible explanation 
for the lack of significant CK elevations with exercise may be attributed to the training 
status of the sample population in this study. The average VO2peak of the 12 subjects in 




, which represents the 99
th
 percentile for maximal 
aerobic power based on age-specific norms prescribed by ACSM (2010). This was higher 
than the VO2peak/max values observed in prior cycling studies conducted by our laboratory 
(Saunders, Kane, and Todd, 2004; Romano-Ely et al., 2006; Saunders, Luden, and 
Herrick, 2007; Valentine et al., 2008; and Saunders et al., 2009). The higher maximal 
aerobic capacity observed in our present study may indicate that the intensity/workload 
prescribed in the glycogen depleting exercise did not provide a stimulus challenging 
enough to impose substantial increases in muscle damage, as measured by serum CK 
responses. Consequently, this impaired our ability to discern the potential effects of 
genotype on variations in CK responses post-exercise. 
Changes in peak muscle function (MVC) measured 4-hours post exercise were 
observed to be more sensitive to significant changes from pre-glycogen exercise levels 
compared to 24-hours post exercise, when they had returned to pre-exercise levels. 
Subjects homozygous for the wild-type allele of ACTN3 R577X sustained significantly 
greater strength losses (66.3 + 40.4 N) 4-hours post exercise than rare allele subjects. The 
increased loss of strength in homozygous wild-type subjects may contribute to slower 





losses in this study differed from the findings of Clarkson et al. (2005), who reported that 
the ACTN3 R577X SNP was not associated with changes in strength post exercise. 
However, Clarkson et al. utilized an eccentric resistance exercise protocol to elicit muscle 
damage, and did not assess strength changes at 4-hours post exercise. One possible factor 
for the increased strength loss in homozygous wild-type subjects may be attributed to 
fiber type characteristics. Vincent et al. (2007) observed that the RR-allele is associated 
with increased distribution of Type IIx fibers (5%, P < 0.05). An increased recruitment of 
these fibers during the high-intensity interval segments of the glycogen depleting 
protocol may potentially elicit greater disruption to the sarcomere structures (e.g. Z-line 
streaming), which would lead to greater declines in MVC 4-hours post exercise. 
However, this development seems unlikely in our study, as it should have also resulted in 
increased CK levels. 
Subjects heterozygous for the IGF-II C13790G SNP demonstrated significantly 
greater declines in peak MVC (33.8 + 16.6 N) than subjects homozygous for the wild-
type allele. Although our sample size was not large enough to include subjects 
homozygous for the rare allele, the results agreed with findings from Devaney et al. 
(2007), who found that the homozygous rare-allele subjects experienced significantly 
greater strength losses (58%) than homozygous wild-type subjects. This would indicate 
that the G allele may be associated with an increased loss of strength with exertional 
muscle damage, regardless of whether resistance or aerobic exercise is performed.  
When genotyped for the IGF2AS A1364C SNP, homozygous rare allele subjects 
demonstrated significantly greater strength losses (30.8 + 23.0 N) than homozygous wild-





greatest strength loss (58%) in homozygous wild-type subjects. The differences may be 
attributed to our smaller population sample, compared to a much larger population 
sample (n = 73) assessed by Devaney et al. Our population was also exclusive to 
Caucasian males, whereas Devaney et al. did not classify their findings according to 
ancestry. A study conducted by the Devine Laboratory at the University of Maryland 
School of Medicine (Institute for Genome Sciences) as part of the International HapMap 
project examined the genotype distribution of 118 Utah residents of Northern and 
Western European ancestry (NCBI, 2003). When genotyped for the IGF2AS A1364C 
SNP, it was observed that 32.2% of the subjects were homozygous for the wild-type 
allele, 44.1% were heterozygous, and 23.7% were homozygous for the rare allele. The 
genotype distributions for this SNP were more closely matched by those reported in 
Devaney et al. (36.2%, 44.7%, 19.1%) than findings in the present study (16.7%, 41.7%, 
41.7%) even though Devaney et al. did not genotype the sample population according to 
ancestry. This may indicate that ancestral variations in this genotype do not significantly 
impact the variables assessed in the present study. Hence, the differences in strength 
losses observed between the present study and those of Devaney et al. may be more 
related to the discrepancies in sample size. 
Physical and mental energy and fatigue ratings, and muscle soreness ratings, were 
observed to be most sensitive to significant changes from pre-glycogen depleting exercise 
to 24-hours post exercise in the CHO control trial, although significant changes were 
observed in several ratings 4-hours post exercise as well. Subjects homozygous for the 
ACTN R577X wild-type allele reported significantly larger declines in physical and 





exercise. This coincided with the above finding of decreased peak muscle function in 
these subjects, which would indicate that the RR wild-type allele of the ACTN3 R577X 
SNP may be more associated with impaired recovery from heavy endurance exercise.  
The IGF2AS G11711T SNP appeared to have the greatest influence on 
physical/mental energy/fatigue and muscle soreness ratings among the genotypes 
analyzed. In particular, 24-hours after the initial exercise, subjects homozygous for the 
wild-type allele reported significantly larger declines in physical and mental energy 
ratings (33.0 + 42.5 mm, 52.0 + 57.5 mm), in conjunction with substantially larger 
elevations in physical and mental fatigue ratings (98.3 + 21.3 mm, 75.3 + 29.3 mm), as 
well as greater increases in muscle soreness ratings (36.8 + 19.8 mm). In addition, as 
discussed above, homozygous wild-type subjects reported larger increases in physical 
and mental fatigue ratings 4-hours post glycogen depleting exercise, which might have 
contributed to their slower ride times during the subsequent exercise for the 20 km and 
final 5 km. These findings would suggest that the GG wild-type allele of the IGF2AS 
G11711T SNP may be more associated with impaired recovery from heavy endurance 
exercise, which would agree with the increased strength loss (58%) and soreness (56 mm) 
reported by Devaney et al. (2007). 
A secondary purpose of the present study was to determine if potentially 
susceptible genotype groups (i.e. those expressing impaired muscle recovery) derived 
greater benefits from carbohydrate and protein ingestion, which have been shown in 
some studies to attenuate post-exercise disruptions in CK, muscle function, and muscle 
soreness. Treatment x time effects were examined for the alleles identified to be 





muscle recovery to be improved with the HCLP treatment. Peak muscle function was 
higher 4-hours post exercise during the HCLP trial than the CHO trial in all genotypes 
analyzed. Furthermore, six out of seven 24-hours post exercise ratings were found to be 
improved with the HCLP trial, with only the physical energy rating showing no changes 
between treatments in subjects homozygous for the IGF2AS G11711T wild-type allele. 
However, none of these treatment x time interactions were statistically significant, 
perhaps due to the small sample size for the genotype groups (n = 2-6). Hence, although 
our findings were preliminary in nature, they warrant further investigations with larger 
population samples to better understand the influence of genotype variations on response 
to carbohydrate-protein supplementation. 
To summarize our findings, when assessing subsequent performance variables, 
we observed that the homozygous XX rare allele for ACTN3 R577X to be associated 
with improved performance during subsequent exercise, whereas the homozygous GG 
wild-type allele for IGF2AS G11711T was associated with slower riding times to 
completion. With regards to recovery variables, we observed that the homozygous RR 
wild-type allele for ACTN3 R577X, the homozygous GG rare allele for IGF-II C13790G, 
the homozygous CC rare allele for IGF2AS A1364C, and the homozygous wild-type GG 
allele for IGF2AS G11711T to be most susceptible to impaired recovery following heavy 
endurance exercise. Peak muscle function appeared to be most sensitive to significant 
changes from pre to 4-hours post glycogen depleting exercise, whereas physical/mental 
energy/fatigue and muscle soreness ratings appeared to be most sensitive to significant 





within genotypes, the HCLP treatment demonstrated a potential tendency to improve 
markers of muscle recovery in „susceptible‟ genotype groups. 
We recommend that future studies recruit larger population samples to analyze 
treatment differences in subjects identified with the specific allele distributions listed 
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1) Genotype variations among subjects led to significant differences in peak muscle 
function (MVC) changes from resting levels to 4-hours following acute heavy 
endurance exercise. 
2) Genotypes variations among subjects led to significant differences in changes for 
physical and mental energy and fatigue ratings, as well as changes in muscle soreness 
ratings, from resting levels to 24-hours following acute heavy endurance exercise.  
3) Subjects with genotypes that were associated with greater increases in the above 
markers of muscle recovery tended to improve these variables with the ingestion of 





























James Madison University 
School of Kinesiology and Recreation Studies 
Consent for Investigative Procedure 
 
I, ______________________, herby agree on _____________ (date) to participate in the 
research project conducted by Dr. Michael Saunders, Dr. Nick Luden, Chris Boop and Qing Goh 
from James Madison University entitled “Altered carbohydrate and protein content in sports 
beverages: Influence on recovery from heavy endurance exercise”. 
 
Purpose 
The purpose of this study is to determine if the ingredients in sports beverages affects short-term 
recovery from heavy cycling exercise.  The proposed study will take approximately 4-5 weeks to 
complete. It will consist of a pretest physical assessment, a familiarization trial, and three 
treatment beverage/recovery trials (detailed below).  The study will take place September, 2009 – 
August 2010, in the Human Performance Laboratory in Godwin Hall, Room 209, JMU. 
 
Subject Responsibility 
I understand that I will undergo the following testing in the study: 
 
Pre-testing Phase: 
Before any physical evaluation is given, I will complete pre-screening forms to insure that I meet 
the study criteria, and that I do not have any risk factors for heavy exercise.  In the process of 
filling out these forms, I will share information regarding my general health and lifestyle with the 
researchers.  In addition, I will notify the researchers if I have any known allergies to milk or milk-
products.  If I meet the criteria for the study, I will complete an assessment of my 
cardiorespiratory fitness and body mass. During this assessment, I will perform an exercise test 
to determine my maximal oxygen uptake (VO2max). To do this, I will ride a stationary cycle at an 
initial workload that is „fairly easy‟.  Workload will be increased every few minutes during the test.  
I will be encouraged to continue to cycle until I request to stop due to fatigue or am unable to 
continue at a cadence >60 rpm.  In order to be included as a participant in the study, I must 
achieve a VO2max of >45 ml/kg/min.  If I meet these criteria, I will complete a familiarization trial, in 
which I perform the procedures described below (in Treatment Phases), without any of the testing 
that follows the Subsequent Exercise Performance Test. 
 
Treatment Beverage/Recovery Trials  
Following pre-testing, I will perform three exercise/recovery phases.  Each of these phases will be 
identical, with the exception that a different sports beverage will be utilized during each phase.  





Two hours following a standardized meal (see below), I will report to the laboratory to 
complete an exercise session on an exercise cycle, consisting of high-intensity aerobic 
intervals.  This trial will take approximately 1-2 hours to complete.  Four hours following the 
initial exercise session, I will perform a Subsequent Exercise Performance Test, consisting of 
30-min of moderate-intensity cycling followed by a 20 km time-trial, which will take 
approximately 40-45 min to complete.  I will be encouraged to treat the trial as a competitive 
event, and give my best effort throughout the trials. Twenty-four hours after the trial, I will 







I will complete the following procedures at various time-points during the protocol: 
Blood draws – Blood will be collected immediately prior to exercise, between the two exercise 
sessions, and 24-hours following exercise.  Each of these blood draws will be conducted by 
inserting a needle into a vein in the upper forearm.  During each sample, small amounts of 
blood (~5-10 ml) will be obtained, and utilized to measure either insulin or markers of muscle 
damage.  Some blood from these collections will also be used to assess genotype variations 
that may be related to muscle damage.  In addition, blood glucose and lactate will be 
assessed once during each during exercise session, using a finger-stick technique, in which 
a very small amount of blood (~0.5 ml) is obtained.  The total amount of blood obtained 
during each trial period is approximately 20 ml, (60 ml over the course of the entire trial).  
This total amount is less than 1/5 of a can of soda, or 15% of the amount given when 
donating blood in a single session (approximately 1 pint, or 473 ml).  The indicated frequency 
of blood draws represents the bare minimum number required to be able to assess the 
dependent measurements indicated within this protocol (muscle damage, insulin, glucose & 
lactate).  Study participants should refrain from donating blood during the study period. 
 
Measurements During Exercise:  
At one time-point during the high-intensity aerobic intervals, and also once during the 
Subsequent Exercise Performance Test, the following measurements will be obtained: 
Metabolic Measurements.  I will have metabolic measurements, such as oxygen uptake, 
ventilation, etc. measured using a SensorMedics metabolic cart.  To do this, I will breathe 
through a mouthpiece/breathing apparatus that collects my expired breath for 
approximately 5 minutes.  The mouthpiece/breathing apparatus will NOT be worn during 
exercise other than at the indicated time-point. 
 
Ratings of Perceived Exertion –I will provide subjective ratings of my exertion level.  I will 
do this by pointing to my corresponding level of exertion (rated numerically from 6-20) on 
a Borg RPE scale.   
 
Heart Rate.  I will have my heart rate measured using a Polar heart rate monitor that is 
worn around my chest throughout each exercise session.   
 
Measurements Before and After Exercise:  
Muscle Soreness and Fatigue Ratings.  I will provide muscle soreness and fatigue ratings 
using a series of 100mm visual analog scales, with 0 indicating (i.e.) no muscle soreness 
and 100 indicating impaired movement due to muscle soreness.  These ratings will be 
obtained immediately prior to the first exercise session (high-intensity aerobic intervals), 
immediately prior to the second exercise session (Subsequent Exercise Performance 
Test), and 24-hours following the first exercise session. 
 
Muscle Function - I will perform a maximal strength test of my quadriceps at the following 
time-points: prior to the first exercise session (high-intensity aerobic intervals), following 
the first exercise session, prior to the second exercise session (Subsequent Exercise 
Performance Test), following the second exercise session, and 24-hours following the 
first exercise session. 
During this test, I will be seated in a modified chair, and asked to push as hard as 
possible against a shin pad that will be connected to a force transducer for about 5 






Sports Beverages and Dietary Controls:  I will consume 625 ml of a sports beverage at the 
following time-points: a) immediately following the first exercise session (high-intensity aerobic 
intervals), b) two-hours following the first exercise session, and c) immediately following the 
second exercise session (Subsequent Exercise Performance Test).  I will perform the study 
protocols on three occasions (separated by 7-14 days each), using a different sports beverage on 
each occasion.  Treatments will contain the same amount of fluid but will contain differing 
amounts of other nutrients (carbohydrates, fat and/or protein).  The specific composition of 
beverages utilized in the study will not be revealed to me during the study.  However, I may 
request this information upon completion of the study.  
 
Two hours prior to each trial, I will receive and consume a small standardized meal.  I may select 
the specific food type from one of three choices, but the specific foods consumed during this 
period will be replicated across each of the three treatment periods.  In addition, I will be 
encouraged to maintain consistent dietary and exercise habits across the duration of the two 
treatment periods.  I will complete a dietary log of all foods consumed during the days prior and 
following each of the exercise sessions.  In addition, I will record the type, amount and intensity 
of all exercise performed during these same time periods.  I will also refrain from heavy exercise 
for 48-hours prior to each exercise test, and will not exercise between the exercise tests and 
follow-up testing (24 hours).   
 
Risks: 
Participants are expected to be honest about disclosing all known risk factors to the researcher. 
There are no known risk factors associated with sports beverage consumption.  The beverages 
may contain milk ingredients, so participants with known milk allergies will be excluded from study 
participation.     
 
According to the American College of Sports Medicine, the risks associated with maximal 
exercise/testing for healthy individuals are very minimal.  Any subjects who do not meet the 
criteria for “low risk” will not be allowed to participate in the study.  In the unlikely event of cardiac 
or other complications during exercise, an emergency plan is in place.  This includes immediate 
access to a phone to call emergency personnel.  In addition, each of the investigators is CPR 
certified.   
 
The exercise protocol may result in minor-moderate levels of muscle soreness and fatigue for 1-2 
days following each exercise session.  However, the level of muscle soreness is expected to be 
lower than levels normally experienced when people perform other „normal‟ activities that are not 
part of their regular exercise routine (i.e. if a cyclist played a game of basketball with friends for 2 
hours).  
 
The risks of blood draws include possible mild bruising, and the risk of transfer of blood-borne 
pathogens.  This risk is considered to be very minimal, and all safety precautions for handing 
blood samples will be followed according to OSHA protocols.  The investigators have been 
trained in phlebotomy and completed JMU blood-borne pathogen training.  The total amount of 
blood removed in these trials is considered very minimal.  Approximately 60-70 ml of blood 
collected during the entire study, which is considered very minimal.  For reference, this is less 
than 1/5 of a can of soda, or 15% of the amount given when donating blood in a single session 
(approximately 1 pint, or 473 ml).   
 
Benefits: 
Benefits include free maximal oxygen uptake testing, use of cutting-edge nutrition products, and a 
$200 stipend for study completion.  In the event that I am unable to complete all testing, 
payments will be distributed in the following manner: $25 for completing the familiarization trial, 







If you have any questions of concerns, please contact Dr. Michael Saunders at 
saundemj@jmu.edu or (540) 568-8121.  In the case of any immediate concerns or adverse 
reactions during the study, contact Dr. Saunders at his cell phone (540) 560-3032.  
 
Confidentiality: 
All data and results will be kept confidential.  Subjects will be assigned an identification code.  At 
no time will a subject‟s name be identified with individual data.  The researcher retains the right to 
use and publish non-identifiable data.  All data will be kept secured in a locked cabinet.  Upon 
completion of the study, all information that matches up individual respondents with their answers 
will be destroyed.  Final aggregate results will be made available to participants upon request.   
 
Freedom of Consent 
Your participation is entirely voluntary.  You are free to choose not to participate.  Should you 
choose to participate, you can withdraw at any time without consequences of any kind. 
 
I have read this consent form and I understand what is being requested of me as a participant in 
this study.  I freely consent to participate.  I have been given satisfactory answers to my 
questions.  The investigator provided me with a copy of this form.  I certify that I am at least 18 
years of age. 
   
Name of Subject  (Printed)  Name of Researcher  (Printed) 
   
Name of Subject  (Signed)  Name of Researcher  (Signed) 
   
  Date    Date 
 
 
For questions about your rights as a research subject, you may contact the chair of JMU’s 
















AHA/ACSM Health/Fitness Facility Pre-participation Screening Questionnaire 
Assess your health status by marking all true statements 
 
History 
You have had: 
   a heart attack 
   heart surgery 
   cardiac catheterization 
   coronary angioplasty (PTCA) 
   pacemaker/implantable cardiac 
   defibrillator/rhythm disturbance 
   heart valve disease 
   heart failure 
   heart transplantation 
   congenital heart disease 
 
Symptoms 
   You experience chest discomfort with exertion 
   You experience unreasonable breathlessness 
   You experience dizziness, fainting, or blackouts 
   You take heart medications 
 
Other Health Issues 
   You have diabetes 
   You have asthma or other lung disease 
   You have burning or cramping sensation in your lower  
   legs when walking short distances 
   You have musculoskeletal problems that limit your  
   physical activity 
   You have concerns about the safety of exercise 




Cardiovascular risk factors 
   You are a man older than 45 years 
   You are a woman older than 55 years, have had a  
   hysterectomy, or are postmenopausal 
   You smoke, or quit smoking within the previous 6 months 
   Your blood pressure is > 140/90 mmHg 
   You do not know your blood pressure 
   You take blood pressure medication 
   Your blood cholesterol level is > 200 mg/dl 
   You do not know your cholesterol level 
   You have a close blood relative who had a heart attack or 
   heart surgery before age 55 (father or brother) or age 65 
       (mother or sister) 
   You are physically inactive (i.e. you get < 30 minutes of  
   physical activity on at least 3 days of the week) 
   You are > 20 pounds overweight 
 
 
   None of the above 
If you marked any of these statements 
in this section, consult your physician 
or other appropriate health care 
provider before engaging in exercise.  
You may need to use a facility with a 
medically qualified staff. 
If you marked two or more of 
the statements in this section, 
you should consult your 
physician or other appropriate 
health care provider before 
engaging in exercise.  You 
might benefit from using a 
facility with a professionally 
qualified exercise staff to guide 
your exercise program. 
You should be able to exercise safely 
without consulting your physician or 
other appropriate health care provider 
in a self-guided program or almost 








Borg Rating of Perceived Exertion Scale (6 - 20) 
 
Exertion RPE 
no exertion at all 6 
extremely light 7 
 8 




somewhat hard 13 
 14 
hard (heavy) 15 
 16 
very hard 17 
 18 
extremely hard 19 









Muscle Soreness Questionnaire 
 




Please place a mark on the line below corresponding to your level of muscle soreness 
 
0 millimeters (left) = complete absence of muscular soreness 




                                                 
        
 
             0 mm                           100 mm 
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